nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at
NCT04244591,"ClinicalTrials.gov processed this data on May 29, 2020",2020-01-23,NA,NA,2020-04-14,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:41:50Z,2020-06-01T09:41:50Z
NCT04252118,"ClinicalTrials.gov processed this data on May 29, 2020",2020-01-27,NA,NA,2020-04-13,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"January 27, 2020",Actual,2020-01-27,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:40:53Z,2020-06-01T09:40:53Z
NCT04251871,"ClinicalTrials.gov processed this data on May 29, 2020",2020-01-28,NA,NA,2020-05-04,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"January 22, 2020",Actual,2020-01-22,May 2020,2020-05-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:40:55Z,2020-06-01T09:40:55Z
NCT04252274,"ClinicalTrials.gov processed this data on May 29, 2020",2020-01-29,NA,NA,2020-04-09,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"January 30, 2020",Actual,2020-01-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DC-COVID-19,,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:40:52Z,2020-06-01T09:40:52Z
NCT04252885,"ClinicalTrials.gov processed this data on May 29, 2020",2020-01-30,NA,NA,2020-01-31,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-31,2020-02-05,Actual,"January 28, 2020",Anticipated,2020-01-28,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Recruiting,NA,Phase 4,125,Anticipated,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:40:48Z,2020-06-01T09:40:48Z
NCT04263402,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:39:22Z,2020-06-01T09:39:22Z
NCT04255017,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:40:32Z,2020-06-01T09:40:32Z
NCT04254874,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:40:33Z,2020-06-01T09:40:33Z
NCT04264533,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-04,NA,NA,2020-03-06,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-10,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial,Recruiting,NA,Phase 2,140,Anticipated,Zhongnan Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:39:10Z,2020-06-01T09:39:10Z
NCT04261270,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:39:40Z,2020-06-01T09:39:40Z
NCT04331613,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-06,NA,NA,2020-03-31,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"January 27, 2020",Actual,2020-01-27,January 2020,2020-01-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,9,Anticipated,Chinese Academy of Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:30Z,2020-06-01T09:30:30Z
NCT04275245,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-06,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,"February 3, 2020",Actual,2020-02-03,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:37:47Z,2020-06-01T09:37:47Z
NCT04261517,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:39:39Z,2020-06-01T09:39:39Z
NCT04269525,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-07,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-17,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection,Recruiting,NA,Phase 2,10,Anticipated,Zhongnan Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:38:33Z,2020-06-01T09:38:33Z
NCT04282902,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:36:47Z,2020-06-01T09:36:47Z
NCT04276688,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:37:38Z,2020-06-01T09:37:38Z
NCT04280224,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-13,NA,NA,2020-04-11,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:37:06Z,2020-06-01T09:37:06Z
NCT04304313,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:33:59Z,2020-06-01T09:33:59Z
NCT04275414,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-14,NA,NA,2020-04-01,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP),Recruiting,NA,Phase 2/Phase 3,20,Anticipated,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:37:46Z,2020-06-01T09:37:46Z
NCT04273763,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-14,NA,NA,2020-04-29,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"February 16, 2020",Actual,2020-02-16,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"May 10, 2020",Anticipated,2020-05-10,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,N/A,18,Actual,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:37:59Z,2020-06-01T09:37:59Z
NCT04279197,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-15,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,,Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu,"A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV",Recruiting,NA,Phase 2,136,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:37:13Z,2020-06-01T09:37:13Z
NCT04273321,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-15,NA,NA,2020-05-08,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,N/A,86,Actual,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:38:02Z,2020-06-01T09:38:02Z
NCT04276896,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:37:36Z,2020-06-01T09:37:36Z
NCT04343794,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-20,NA,NA,2020-04-13,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,NA,N/A,200,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:52Z,2020-06-01T09:28:52Z
NCT04280705,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-20,NA,NA,2020-05-06,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"February 21, 2020",Actual,2020-02-21,"April 16, 2020",2020-04-16,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,800,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:37:02Z,2020-06-01T09:37:02Z
NCT04280588,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-20,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Fingolimod in COVID-19,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,First Affiliated Hospital of Fujian Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:37:04Z,2020-06-01T09:37:04Z
NCT04283461,"ClinicalTrials.gov processed this data on June 02, 2020",2020-02-21,NA,NA,2020-05-28,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"March 16, 2020",Actual,2020-03-16,"May 26, 2020",2020-05-26,"November 22, 2021",Anticipated,2021-11-22,"November 22, 2021",Anticipated,2021-11-22,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Recruiting,NA,Phase 1,155,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,13,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-03T08:32:41Z,2020-06-03T08:32:41Z
NCT04288102,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-24,NA,NA,2020-04-05,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,,Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19),"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence",Recruiting,NA,Phase 2,90,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:36:07Z,2020-06-01T09:36:07Z
NCT04291729,"ClinicalTrials.gov processed this data on May 29, 2020",2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:35:42Z,2020-06-01T09:35:42Z
NCT04292730,"ClinicalTrials.gov processed this data on June 05, 2020",2020-02-28,NA,NA,2020-05-29,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"March 15, 2020",Actual,2020-03-15,May 2020,2020-05-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,"Active, not recruiting",NA,Phase 3,1600,Anticipated,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:44:21Z,2020-06-07T08:44:21Z
NCT04292899,"ClinicalTrials.gov processed this data on June 05, 2020",2020-02-28,NA,NA,2020-05-29,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,"Active, not recruiting",NA,Phase 3,6000,Anticipated,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:44:20Z,2020-06-07T08:44:20Z
NCT04308317,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:33:30Z,2020-06-01T09:33:30Z
NCT04304053,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-05,NA,NA,2020-04-14,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"June 15, 2020",Anticipated,2020-06-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Recruiting,NA,Phase 3,3040,Anticipated,Fundacio Lluita Contra la SIDA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2020-06-01T09:34:02Z,2020-06-01T09:34:02Z
NCT04299724,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:34:33Z,2020-06-01T09:34:33Z
NCT04303507,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-06,NA,NA,2020-05-20,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"April 29, 2020",Actual,2020-04-29,March 2020,2020-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-06-01T09:34:05Z,2020-06-01T09:34:05Z
NCT04306055,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-08,NA,NA,2020-04-09,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,"April 3, 2020",Actual,2020-04-03,"March 13, 2020",Actual,2020-03-13,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,N/A,19491,Actual,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:33:45Z,2020-06-01T09:33:45Z
NCT04310228,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-09,NA,NA,2020-04-08,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"March 8, 2020",Actual,2020-03-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,N/A,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:33:10Z,2020-06-01T09:33:10Z
NCT04305457,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-09,NA,NA,2020-05-22,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"March 21, 2020",Actual,2020-03-21,May 2020,2020-05-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,Recruiting,NA,Phase 2,240,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:33:49Z,2020-06-01T09:33:49Z
NCT04305106,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-09,NA,NA,2020-03-24,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,BEST-RCT,,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,N/A,140,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:33:53Z,2020-06-01T09:33:53Z
NCT04304690,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-09,NA,NA,2020-04-10,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"October 16, 2020",Anticipated,2020-10-16,"July 16, 2020",Anticipated,2020-07-16,NA,Interventional,SEROCOV,,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic",Recruiting,NA,N/A,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:33:56Z,2020-06-01T09:33:56Z
NCT04306393,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-10,NA,NA,2020-05-20,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"March 21, 2020",Actual,2020-03-21,May 2020,2020-05-31,"March 21, 2022",Anticipated,2022-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:33:44Z,2020-06-01T09:33:44Z
NCT04308668,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-11,NA,NA,2020-04-28,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-05-01,Actual,"March 17, 2020",Actual,2020-03-17,April 2020,2020-04-30,"May 14, 2020",Anticipated,2020-05-14,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3000,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,At time of publication,To be publicly provided,http://covidpep.umn.edu,Yes,De-identified dataset will be included with publication.,2020-06-01T09:33:28Z,2020-06-01T09:33:28Z
NCT04311177,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-13,NA,NA,2020-04-29,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-04,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Recruiting,NA,Phase 2,580,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:33:04Z,2020-06-01T09:33:04Z
NCT04316377,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-13,NA,NA,2020-06-04,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"March 25, 2020",Actual,2020-03-25,June 2020,2020-06-30,"March 3, 2025",Anticipated,2025-03-03,"May 25, 2020",Actual,2020-05-25,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 4,53,Actual,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-08T08:33:01Z,2020-06-08T08:33:01Z
NCT04315948,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-13,NA,NA,2020-06-03,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,3100,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:33:02Z,2020-06-08T08:33:02Z
NCT04312009,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-13,NA,NA,2020-06-03,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"April 13, 2020",Actual,2020-04-13,June 2020,2020-06-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-08T08:33:07Z,2020-06-08T08:33:07Z
NCT04315480,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-14,NA,NA,2020-04-09,2020-03-18,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 12, 2020",Actual,2020-03-12,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,"April 9, 2020",Anticipated,2020-04-09,NA,Interventional,NA,,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia,"Active, not recruiting",NA,Phase 2,38,Actual,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:32:34Z,2020-06-01T09:32:34Z
NCT04311697,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-14,NA,NA,2020-06-02,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Recruiting,NA,Phase 2,144,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-08T08:33:08Z,2020-06-08T08:33:08Z
NCT04315298,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-15,NA,NA,2020-04-02,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"March 9, 2021",Anticipated,2021-03-09,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Regeneron Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://errs.regeneron.com/external,Yes,All IPD that underlie publicly available results will be considered for sharing,2020-06-01T09:32:36Z,2020-06-01T09:32:36Z
NCT04313322,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:32:49Z,2020-06-01T09:32:49Z
NCT04313127,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-15,NA,NA,2020-05-16,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Active, not recruiting",NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2020-06-01T09:32:50Z,2020-06-01T09:32:50Z
NCT04313023,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-16,NA,NA,2020-06-02,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,June 2020,Anticipated,2020-06-30,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,NA,Phase 2,200,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:33:05Z,2020-06-08T08:33:05Z
NCT04312997,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-16,NA,NA,2020-06-02,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,June 2020,Anticipated,2020-06-30,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,NA,Phase 2,100,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:33:06Z,2020-06-08T08:33:06Z
NCT04323514,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-18,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"March 13, 2021",Anticipated,2021-03-13,"March 13, 2021",Anticipated,2021-03-13,NA,Interventional,NA,,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,N/A,500,Anticipated,University of Palermo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:32Z,2020-06-01T09:31:32Z
NCT04321174,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-18,NA,NA,2020-04-17,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,NA,Phase 3,1220,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2020-06-01T09:31:50Z,2020-06-01T09:31:50Z
NCT04315896,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-18,NA,NA,2020-04-15,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 22, 2021",Anticipated,2021-03-22,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),Recruiting,NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-06-01T09:32:30Z,2020-06-01T09:32:30Z
NCT04323527,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-19,NA,NA,2020-04-13,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Recruiting,NA,Phase 2,440,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2020-06-01T09:31:32Z,2020-06-01T09:31:32Z
NCT04320056,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-19,NA,NA,2020-04-20,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"October 31, 2021",Anticipated,2021-10-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Recruiting,NA,N/A,216,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2020-06-01T09:31:58Z,2020-06-01T09:31:58Z
NCT04318015,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-19,NA,NA,2020-04-15,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:32:13Z,2020-06-01T09:32:13Z
NCT04317092,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-19,NA,NA,2020-04-03,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,TOCIVID-19,,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,400,Anticipated,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:32:22Z,2020-06-01T09:32:22Z
NCT04317040,"ClinicalTrials.gov processed this data on June 02, 2020",2020-03-19,NA,NA,2020-05-27,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Recruiting,NA,Phase 3,230,Anticipated,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-03T08:32:11Z,2020-06-03T08:32:11Z
NCT04324606,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-20,NA,NA,2020-05-22,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 23, 2020",Actual,2020-04-23,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:25Z,2020-06-01T09:31:25Z
NCT04319900,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:32:00Z,2020-06-01T09:32:00Z
NCT04319445,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-20,NA,NA,2020-04-22,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 22, 2020",Actual,2020-03-22,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Recruiting,NA,N/A,200,Anticipated,Wake Forest University Health Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:32:03Z,2020-06-01T09:32:03Z
NCT04318444,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-20,NA,NA,2020-04-23,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 29, 2020",Actual,2020-03-29,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:32:10Z,2020-06-01T09:32:10Z
NCT04318431,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-20,NA,NA,2020-06-02,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 14, 2020",Actual,2020-04-14,June 2020,2020-06-30,June 2020,Anticipated,2020-06-30,"May 12, 2020",Actual,2020-05-12,NA,Interventional,COVILLE,,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.","Active, not recruiting",NA,N/A,605,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:58Z,2020-06-08T08:32:58Z
NCT04325867,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,eCardioCovid19,,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic",Recruiting,NA,N/A,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"If this platform will be functional, we are willing to provide the system and protocols and know-how to other centers in Romania.",2020-06-01T09:31:12Z,2020-06-01T09:31:12Z
NCT04320953,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-21,NA,NA,2020-04-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 9, 2020",Actual,2020-04-09,"March 26, 2020",Actual,2020-03-26,NA,Interventional,NA,,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,N/A,5,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:52Z,2020-06-01T09:31:52Z
NCT04320238,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:31:57Z,2020-06-01T09:31:57Z
NCT04319731,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-22,NA,NA,2020-04-15,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"March 20, 2021",Anticipated,2021-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NA,,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,NA,Early Phase 1,10,Anticipated,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:32:01Z,2020-06-01T09:32:01Z
NCT04328961,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-05-12,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"March 31, 2020",Actual,2020-03-31,May 2020,2020-05-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Recruiting,NA,Phase 2/Phase 3,2000,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-06-01T09:30:49Z,2020-06-01T09:30:49Z
NCT04328129,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-05-14,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,,Household Transmission Investigation Study for COVID-19 in French Guiana,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana,Recruiting,NA,N/A,450,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:55Z,2020-06-01T09:30:55Z
NCT04323345,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-04-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:33Z,2020-06-01T09:31:33Z
NCT04322682,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-04-22,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,NA,Phase 3,6000,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:39Z,2020-06-01T09:31:39Z
NCT04322396,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-05-07,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"March 31, 2021",Anticipated,2021-03-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,ProPAC-COVID,,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,"Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Recruiting,NA,Phase 2,226,Anticipated,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:41Z,2020-06-01T09:31:41Z
NCT04322344,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:42Z,2020-06-01T09:31:42Z
NCT04321616,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2020-06-01T09:31:47Z,2020-06-01T09:31:47Z
NCT04321278,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-05-22,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Recruiting,NA,Phase 3,440,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:49Z,2020-06-01T09:31:49Z
NCT04321096,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-23,NA,NA,2020-04-28,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 4, 2020",Actual,2020-04-04,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,580,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2020-06-01T09:31:51Z,2020-06-01T09:31:51Z
NCT04321421,"ClinicalTrials.gov processed this data on June 01, 2020",2020-03-23,NA,NA,2020-05-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"March 17, 2020",Actual,2020-03-17,May 2020,2020-05-31,"May 7, 2020",Actual,2020-05-07,"April 28, 2020",Actual,2020-04-28,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,N/A,49,Actual,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2020-06-02T08:29:47Z,2020-06-02T08:29:47Z
NCT04320615,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-23,NA,NA,2020-05-28,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,450,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.
Further details on Roche's criteria for eligible studies are available here: https://vivli.org.
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2020-06-06T08:50:59Z,2020-06-06T08:50:59Z
NCT04330690,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-23,NA,NA,2020-06-04,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"May 18, 2022",Anticipated,2022-05-18,"March 18, 2022",Anticipated,2022-03-18,NA,Interventional,CATCO,,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)",Recruiting,NA,Phase 2,2900,Anticipated,Sunnybrook Health Sciences Centre,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Unknown and variable,NA,NA,Yes,"As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization.
Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.",2020-06-08T08:32:44Z,2020-06-08T08:32:44Z
NCT04327349,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,N/A,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:31:02Z,2020-06-01T09:31:02Z
NCT04326920,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-24,NA,NA,2020-04-23,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"March 24, 2020",Actual,2020-03-24,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,SARPAC,,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Recruiting,NA,Phase 4,80,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:04Z,2020-06-01T09:31:04Z
NCT04322773,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-24,NA,NA,2020-04-05,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,TOCIVID,,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Recruiting,NA,Phase 2,200,Anticipated,Frederiksberg University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:31:38Z,2020-06-01T09:31:38Z
NCT04322565,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-24,NA,NA,2020-05-14,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"July 20, 2020",Anticipated,2020-07-20,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,ColCOVID-19,,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia,Recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2020-06-01T09:31:40Z,2020-06-01T09:31:40Z
NCT04321993,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-24,NA,NA,2020-05-15,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,NA,Phase 2,1000,Anticipated,Nova Scotia Health Authority,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:44Z,2020-06-01T09:31:44Z
NCT04322123,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-24,NA,NA,2020-05-28,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients","Active, not recruiting",NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-06T08:50:58Z,2020-06-06T08:50:58Z
NCT04371601,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",NA,Early Phase 1,60,Actual,Fuzhou General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:12Z,2020-06-01T09:25:12Z
NCT04353271,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-27,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,THICK,,Trial of Hydroxychloroquine In Covid-19 Kinetics,A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics,"Active, not recruiting",NA,Phase 2/Phase 3,58,Anticipated,University of South Alabama,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:38Z,2020-06-01T09:27:38Z
NCT04336462,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"February 15, 2020",Actual,2020-02-15,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"February 21, 2020",Actual,2020-02-21,NA,Interventional,COVID-19,,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,"A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19",Recruiting,NA,N/A,100,Anticipated,Shanghai Asclepius Meditec Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:49Z,2020-06-01T09:29:49Z
NCT04327206,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-05-25,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"March 30, 2020",Actual,2020-03-30,May 2020,2020-05-31,"March 30, 2022",Anticipated,2022-03-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers Following Coronavirus Exposure (BRACE) Trial,Recruiting,NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2020-06-01T09:31:03Z,2020-06-01T09:31:03Z
NCT04326452,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"June 1, 2020",Anticipated,2020-06-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,N/A,15,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:07Z,2020-06-01T09:31:07Z
NCT04325893,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-05-15,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,HYCOVID,,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study",Recruiting,NA,Phase 3,1300,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:10Z,2020-06-01T09:31:10Z
NCT04325061,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-15,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,DEXA-COVID19,,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Recruiting,NA,Phase 4,200,Anticipated,Dr. Negrin University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:20Z,2020-06-01T09:31:20Z
NCT04324996,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:21Z,2020-06-01T09:31:21Z
NCT04324528,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"November 26, 2020",Anticipated,2020-11-26,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,CYCOV,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,NA,N/A,30,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:25Z,2020-06-01T09:31:25Z
NCT04324489,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-05-01,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,N/A,4,Actual,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:25Z,2020-06-01T09:31:25Z
NCT04324463,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-21,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,ACT COVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Recruiting,NA,Phase 3,1500,Anticipated,Population Health Research Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:31:25Z,2020-06-01T09:31:25Z
NCT04324073,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-14,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:31:28Z,2020-06-01T09:31:28Z
NCT04324021,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-25,NA,NA,2020-04-08,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNÎ³) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.",Recruiting,NA,Phase 2/Phase 3,54,Anticipated,Swedish Orphan Biovitrum,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:29Z,2020-06-01T09:31:29Z
NCT04328285,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-25,NA,NA,2020-05-29,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVIDAXIS,,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial,"Active, not recruiting",NA,Phase 3,1200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-06T08:50:47Z,2020-06-06T08:50:47Z
NCT04327505,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-25,NA,NA,2020-06-03,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVID-19-HBO,,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,"A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:49Z,2020-06-08T08:32:49Z
NCT04355962,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-04-24,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-24,2020-04-27,Actual,"April 23, 2020",Actual,2020-04-23,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Sevoflurane in COVID-19 ARDS (SevCov),Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial,Recruiting,NA,Phase 3,64,Anticipated,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:15Z,2020-06-01T09:27:15Z
NCT04329533,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-04-19,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-19,2020-04-21,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Recruiting,NA,N/A,150,Anticipated,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:46Z,2020-06-01T09:30:46Z
NCT04326790,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-05-06,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,GRECCO-19,,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,NA,Phase 2,180,Anticipated,National and Kapodistrian University of Athens,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:31:05Z,2020-06-01T09:31:05Z
NCT04326426,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-04-16,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Enrolling by invitation,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:31:07Z,2020-06-01T09:31:07Z
NCT04326036,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-03-30,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Healeon Medical Inc,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,In discussion phase,2020-06-01T09:31:10Z,2020-06-01T09:31:10Z
NCT04325906,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-04-20,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Recruiting,NA,N/A,346,Anticipated,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:10Z,2020-06-01T09:31:10Z
NCT04324190,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-26,NA,NA,2020-04-11,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DISPOSE,,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Recruiting,NA,N/A,600,Anticipated,International Psychoanalytic University Berlin,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:31:28Z,2020-06-01T09:31:28Z
NCT04327388,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-26,NA,NA,2020-05-29,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"March 28, 2020",Actual,2020-03-28,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Recruiting,NA,Phase 3,400,Anticipated,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-06-06T08:50:50Z,2020-06-06T08:50:50Z
NCT04327401,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-26,NA,NA,2020-06-02,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 13, 2020",Actual,2020-04-13,June 2020,2020-06-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,CoDEX,,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)",Recruiting,NA,Phase 3,350,Anticipated,Hospital Sirio-Libanes,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:49Z,2020-06-08T08:32:49Z
NCT04344379,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-27,NA,NA,2020-04-23,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,PREP-COVID,,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus,Recruiting,NA,Phase 3,900,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:47Z,2020-06-01T09:28:47Z
NCT04331899,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-27,NA,NA,2020-04-23,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"April 24, 2020",Actual,2020-04-24,March 2020,2020-03-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,COVID-Lambda,,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19",Recruiting,NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No current plan to share the data.,2020-06-01T09:30:27Z,2020-06-01T09:30:27Z
NCT04328467,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-27,NA,NA,2020-05-26,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,"Active, not recruiting",NA,Phase 3,1500,Actual,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:30:53Z,2020-06-01T09:30:53Z
NCT04328441,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-27,NA,NA,2020-04-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,"December 25, 2020",Anticipated,2020-12-25,"October 25, 2020",Anticipated,2020-10-25,NA,Interventional,BCG-CORONA,,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.",Recruiting,NA,Phase 3,1500,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,The results of this study will be disclosed unreservedly at the end of the study.,2020-06-01T09:30:53Z,2020-06-01T09:30:53Z
NCT04328012,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-27,NA,NA,2020-04-06,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,COVIDMED,,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Bassett Healthcare,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:56Z,2020-06-01T09:30:56Z
NCT04328493,"ClinicalTrials.gov processed this data on June 02, 2020",2020-03-27,NA,NA,2020-05-27,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,VICO,,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Recruiting,NA,Phase 2,250,Anticipated,"Oxford University Clinical Research Unit, Vietnam",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-03T08:31:56Z,2020-06-03T08:31:56Z
NCT04336254,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-28,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19ï¼ša Single-center, Prospective, Randomised Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Renmin Hospital of Wuhan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:51Z,2020-06-01T09:29:51Z
NCT04329195,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-28,NA,NA,2020-06-02,2020-03-28,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"August 9, 2020",Anticipated,2020-08-09,"May 9, 2020",Actual,2020-05-09,NA,Interventional,ACORES-2,,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study,Recruiting,NA,Phase 3,554,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:46Z,2020-06-08T08:32:46Z
NCT04333368,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-29,NA,NA,2020-05-19,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"July 31, 2021",Anticipated,2021-07-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,STROMA-CoV2,,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:30:14Z,2020-06-01T09:30:14Z
NCT04331054,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-29,NA,NA,2020-04-16,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"July 13, 2020",Anticipated,2020-07-13,"July 13, 2020",Anticipated,2020-07-13,NA,Interventional,INHASCO,,Protective Role of Inhaled Steroids for Covid-19 Infection,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,NA,Phase 3,436,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:34Z,2020-06-01T09:30:34Z
NCT04329611,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-29,NA,NA,2020-05-14,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 13, 2020",Actual,2020-04-13,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.",Recruiting,NA,Phase 3,1660,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,24 months after study close out.,pending.,NA,Yes,NA,2020-06-01T09:30:46Z,2020-06-01T09:30:46Z
NCT04348370,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-05-24,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,BADAS,,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,Recruiting,NA,Phase 4,1800,Anticipated,Texas A&M University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2020-06-01T09:28:14Z,2020-06-01T09:28:14Z
NCT04332107,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-05-21,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 22, 2020",Actual,2020-05-22,May 2020,2020-05-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,ACTION,,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Recruiting,NA,Phase 3,2271,Anticipated,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:30:26Z,2020-06-01T09:30:26Z
NCT04331600,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-05-21,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Recruiting,NA,Phase 4,400,Anticipated,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:30Z,2020-06-01T09:30:30Z
NCT04331470,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,NA,,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease,Recruiting,NA,Phase 2/Phase 3,30,Anticipated,Fasa University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,between 1 to 2 months after analyzing the raw data.,Results will be available in Journals.,http://journal.fums.ac.ir/en,Yes,All IPD that underlie results in a publication and is comply with ethics will be revealed.,2020-06-01T09:30:32Z,2020-06-01T09:30:32Z
NCT04330300,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CORONACION,,Coronavirus (COVID-19) ACEi/ARB Investigation,The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial,Recruiting,NA,Phase 4,2414,Anticipated,"National University of Ireland, Galway, Ireland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,12-24 months,To be determined,NA,Yes,NA,2020-06-01T09:30:41Z,2020-06-01T09:30:41Z
NCT04329923,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-04-27,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"December 1, 2021",Anticipated,2021-12-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,PATCH,,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Recruiting,NA,Phase 2,400,Anticipated,University of Pennsylvania,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2020-06-01T09:30:44Z,2020-06-01T09:30:44Z
NCT04328480,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-30,NA,NA,2020-04-28,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,COLCOVID,,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,The ECLA PHRI COLCOVID Trial,Recruiting,NA,Phase 3,2500,Anticipated,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:53Z,2020-06-01T09:30:53Z
NCT04329832,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-30,NA,NA,2020-05-29,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"March 30, 2020",Actual,2020-03-30,May 2020,2020-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HAHPS,,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial,Recruiting,NA,Phase 2,300,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-06-07T08:43:26Z,2020-06-07T08:43:26Z
NCT04376515,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-05-05,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"September 1, 2020",Anticipated,2020-09-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),HOPE Intervention for COVID-19,"Active, not recruiting",NA,N/A,300,Actual,"University of California, Irvine",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:37Z,2020-06-01T09:24:37Z
NCT04352348,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-05-11,2020-04-14,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"March 31, 2022",Anticipated,2022-03-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,COVIDeF,,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France),Recruiting,NA,N/A,2000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:44Z,2020-06-01T09:27:44Z
NCT04347174,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-05-08,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Recruiting,NA,N/A,40,Anticipated,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:27Z,2020-06-01T09:28:27Z
NCT04342182,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-05-15,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,ConCoVid-19,,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19,Recruiting,NA,Phase 2/Phase 3,426,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:02Z,2020-06-01T09:29:02Z
NCT04336332,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-05-06,2020-04-02,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Recruiting,NA,Phase 2,160,Anticipated,"Rutgers, The State University of New Jersey",,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:50Z,2020-06-01T09:29:50Z
NCT04335123,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-04-22,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Recruiting,NA,Phase 1,50,Anticipated,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:59Z,2020-06-01T09:29:59Z
NCT04333355,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-05-06,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"December 20, 2020",Anticipated,2020-12-20,NA,Interventional,NA,,Safety in Convalescent Plasma Transfusion to COVID-19,Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 1,20,Anticipated,Hospital San Jose Tec de Monterrey,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:30:14Z,2020-06-01T09:30:14Z
NCT04332094,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-04-05,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,TOCOVID,,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2,276,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:26Z,2020-06-01T09:30:26Z
NCT04331808,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-04-26,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 30, 2020",Actual,2020-03-30,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),"Active, not recruiting",NA,Phase 2,228,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:30:28Z,2020-06-01T09:30:28Z
NCT04331366,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-04-10,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Recruiting,NA,N/A,5,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:32Z,2020-06-01T09:30:32Z
NCT04330638,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-04-23,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,COV-AID,,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Recruiting,NA,Phase 3,342,Anticipated,"University Hospital, Ghent",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:38Z,2020-06-01T09:30:38Z
NCT04329650,"ClinicalTrials.gov processed this data on May 29, 2020",2020-03-31,NA,NA,2020-04-16,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",Recruiting,NA,Phase 2,200,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:45Z,2020-06-01T09:30:45Z
NCT04343651,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-31,NA,NA,2020-06-01,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"April 4, 2021",Anticipated,2021-04-04,"December 4, 2020",Anticipated,2020-12-04,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,75,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:32:26Z,2020-06-08T08:32:26Z
NCT04335305,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-31,NA,NA,2020-06-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"July 1, 2020",Anticipated,2020-07-01,June 2020,2020-06-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,COPERNICO,,Checkpoint Blockade in COVID-19 Pandemic,"A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy",Recruiting,NA,Phase 2,24,Anticipated,MedSIR,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:40Z,2020-06-08T08:32:40Z
NCT04332991,"ClinicalTrials.gov processed this data on June 05, 2020",2020-03-31,NA,NA,2020-06-02,2020-03-31,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 2, 2020",Actual,2020-04-02,June 2020,2020-06-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Recruiting,NA,Phase 3,510,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:43Z,2020-06-08T08:32:43Z
NCT04339712,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-21,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Recruiting,NA,Phase 2,40,Anticipated,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:26Z,2020-06-01T09:29:26Z
NCT04338009,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,REPLACECOVID,,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Enrolling by invitation,NA,N/A,152,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Not making it available,2020-06-01T09:29:38Z,2020-06-01T09:29:38Z
NCT04335279,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-23,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 3, 2020",Anticipated,2020-06-03,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SPIN-CHAT,,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Recruiting,NA,N/A,195,Anticipated,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2020-06-01T09:29:58Z,2020-06-01T09:29:58Z
NCT04335136,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-05-04,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,APN01-COVID-19,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recruiting,NA,Phase 2,200,Anticipated,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:59Z,2020-06-01T09:29:59Z
NCT04335097,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-05-11,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 22, 2020",Actual,2020-04-22,May 2020,2020-05-31,"December 20, 2025",Anticipated,2025-12-20,"April 8, 2021",Anticipated,2021-04-08,NA,Interventional,HSC19,,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,"Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study",Recruiting,NA,N/A,214,Anticipated,Oslo University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:59Z,2020-06-01T09:29:59Z
NCT04334265,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study",Recruiting,NA,N/A,750,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:08Z,2020-06-01T09:30:08Z
NCT04334044,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-16,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Grupo Cooperativo de HemopatÃ­as Malignas,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:09Z,2020-06-01T09:30:09Z
NCT04333914,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-05-07,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,IMMUNONCOVID,,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,"Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) vs Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection",Recruiting,NA,Phase 2,273,Anticipated,Centre Leon Berard,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:10Z,2020-06-01T09:30:10Z
NCT04333589,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"September 15, 2020",Anticipated,2020-09-15,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",Recruiting,NA,N/A,210,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:12Z,2020-06-01T09:30:12Z
NCT04333550,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-30,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Application of Desferal to Treat COVID-19,Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:30:12Z,2020-06-01T09:30:12Z
NCT04333420,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-15,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,PANAMO,,"Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2/Phase 3,130,Anticipated,InflaRx GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:14Z,2020-06-01T09:30:14Z
NCT04333407,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-08,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,C-19-ACS,,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,NA,N/A,3170,Anticipated,Imperial College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No individual participant data will be shared with other researchers or organisations. Anonymised data might be shared with other research organisations,2020-06-01T09:30:14Z,2020-06-01T09:30:14Z
NCT04333225,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-05-04,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"July 30, 2020",Anticipated,2020-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,"Active, not recruiting",NA,Phase 2,228,Actual,Baylor Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:16Z,2020-06-01T09:30:16Z
NCT04331834,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-03,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 3, 2020",Anticipated,2020-10-03,NA,Interventional,PrEP_COVID,,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial",Recruiting,NA,Phase 3,440,Anticipated,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:28Z,2020-06-01T09:30:28Z
NCT04331795,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-01,NA,NA,2020-04-29,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COVIDOSE,,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Recruiting,NA,Phase 2,50,Anticipated,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:28Z,2020-06-01T09:30:28Z
NCT04347226,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-29,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19,Recruiting,NA,Phase 2,138,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:27Z,2020-06-01T09:28:27Z
NCT04345523,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,ConPlas-19,,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 2,278,Anticipated,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:39Z,2020-06-01T09:28:39Z
NCT04340349,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-05-11,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"August 20, 2020",Anticipated,2020-08-20,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,ELEVATE,,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial),Enrolling by invitation,NA,Early Phase 1,140,Anticipated,Instituto Nacional de Rehabilitacion,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"Under Mexican Law, we are not able to provide IPD",2020-06-01T09:29:19Z,2020-06-01T09:29:19Z
NCT04339660,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-05,2020-04-05,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-09,Actual,"February 1, 2020",Actual,2020-02-01,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:26Z,2020-06-01T09:29:26Z
NCT04337541,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-05,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Recruiting,NA,N/A,6000,Anticipated,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:41Z,2020-06-01T09:29:41Z
NCT04335786,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-05-25,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,"PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease",Recruiting,NA,Phase 4,651,Anticipated,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:54Z,2020-06-01T09:29:54Z
NCT04335071,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-27,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 26, 2020",Actual,2020-04-26,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,CORON-ACT,,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),"CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)",Recruiting,NA,Phase 2,100,Anticipated,"University Hospital Inselspital, Berne",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:59Z,2020-06-01T09:29:59Z
NCT04334928,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-27,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,EPICOS,,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Recruiting,NA,Phase 3,4000,Anticipated,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:00Z,2020-06-01T09:30:00Z
NCT04334850,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-05-25,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,MultiCov,,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Recruiting,NA,N/A,194,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:30:01Z,2020-06-01T09:30:01Z
NCT04334460,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-05-20,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment",Recruiting,NA,Phase 2,120,Anticipated,Blade Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:30:06Z,2020-06-01T09:30:06Z
NCT04334382,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-02,NA,NA,2020-04-07,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HyAzOUT,,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial,Recruiting,NA,Phase 3,1550,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-06-01T09:30:07Z,2020-06-01T09:30:07Z
NCT04334629,"ClinicalTrials.gov processed this data on June 01, 2020",2020-04-02,NA,NA,2020-05-26,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 26, 2020",Anticipated,2020-05-26,May 2020,2020-05-31,"May 25, 2021",Anticipated,2021-05-25,"September 25, 2020",Anticipated,2020-09-25,NA,Interventional,LIBERATE,,LIBERATE Trial in COVID-19,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",Recruiting,NA,Phase 4,230,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-02T08:29:31Z,2020-06-02T08:29:31Z
NCT04348409,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-04-20,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 12, 2020",Anticipated,2020-04-12,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.",Recruiting,NA,N/A,50,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-06-01T09:28:14Z,2020-06-01T09:28:14Z
NCT04343053,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-05-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,ATTAC-Co,,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection",Recruiting,NA,N/A,60,Anticipated,University Hospital of Ferrara,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,After specific request to study PIs,2020-06-01T09:28:57Z,2020-06-01T09:28:57Z
NCT04340544,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-05-08,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"September 30, 2022",Anticipated,2022-09-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,COMIHY,,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Recruiting,NA,Phase 3,2700,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:15Z,2020-06-01T09:29:15Z
NCT04337008,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SRA-COV,,Renin Angiotensin System - CoronaVirus,Renin Angiotensin System - CoronaVirus,Recruiting,NA,N/A,50,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:45Z,2020-06-01T09:29:45Z
NCT04336904,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Active, not recruiting",NA,Phase 3,100,Anticipated,ASST Fatebenefratelli Sacco,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:29:46Z,2020-06-01T09:29:46Z
NCT04336774,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-05-06,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,"November 9, 2020",Anticipated,2020-11-09,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,CAPTION AI,,CAPTION AI to Minimize Risk of COVID Exposure,Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19,Recruiting,NA,N/A,500,Anticipated,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:47Z,2020-06-01T09:29:47Z
NCT04335552,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Recruiting,NA,Phase 2,500,Anticipated,Duke University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:56Z,2020-06-01T09:29:56Z
NCT04336410,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-03,NA,NA,2020-06-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1,120,Anticipated,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2020-06-08T08:32:37Z,2020-06-08T08:32:37Z
NCT04342650,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-04,NA,NA,2020-04-10,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,CloroCOVID19II,,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Recruiting,NA,Phase 2,210,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2020-06-01T09:29:00Z,2020-06-01T09:29:00Z
NCT04341116,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-04,NA,NA,2020-05-20,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"April 11, 2020",Actual,2020-04-11,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,144,Anticipated,I-Mab Biopharma Co. Ltd.,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:10Z,2020-06-01T09:29:10Z
NCT04338568,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-04,NA,NA,2020-04-14,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,SCOUT,,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia,Recruiting,NA,N/A,50,Anticipated,Hasselt University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,no plan,2020-06-01T09:29:34Z,2020-06-01T09:29:34Z
NCT04345861,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-05,NA,NA,2020-04-22,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,"April 6, 2021",Anticipated,2021-04-06,"September 6, 2020",Anticipated,2020-09-06,NA,Interventional,COVIDOC,,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,"University Hospital, Montpellier",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:36Z,2020-06-01T09:28:36Z
NCT04341675,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-05,NA,NA,2020-05-18,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,SCOPE,,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial),Recruiting,NA,Phase 2,30,Anticipated,University of Cincinnati,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,De-identified aggregate data will be made available to other researchers on a case-by-case basis.,2020-06-01T09:29:06Z,2020-06-01T09:29:06Z
NCT04338828,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-05,NA,NA,2020-05-18,2020-04-05,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 18, 2020",Actual,2020-04-18,May 2020,2020-05-31,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NO COV-ED,,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department,Recruiting,NA,Phase 2,260,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:33Z,2020-06-01T09:29:33Z
NCT04338841,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-05,NA,NA,2020-04-09,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Recruiting,NA,N/A,4000,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:32Z,2020-06-01T09:29:32Z
NCT04343092,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-05,NA,NA,2020-06-03,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients: A Pilot Randomized Study,Completed,NA,Phase 1,100,Actual,University of Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:27Z,2020-06-08T08:32:27Z
NCT04349631,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-06,NA,NA,2020-04-28,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"May 7, 2020",Anticipated,2020-05-07,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease",Enrolling by invitation,NA,Phase 2,56,Anticipated,Hope Biosciences,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:04Z,2020-06-01T09:28:04Z
NCT04346797,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-06,NA,NA,2020-04-23,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,CORIMUNO19-ECU,,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:30Z,2020-06-01T09:28:30Z
NCT04337918,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-06,NA,NA,2020-05-10,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Recruiting,NA,Phase 2,200,Anticipated,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:39Z,2020-06-01T09:29:39Z
NCT04344951,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-06,NA,NA,2020-05-29,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,HOPE,,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,NA,Phase 2,60,Anticipated,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-07T08:42:56Z,2020-06-07T08:42:56Z
NCT04340557,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-06,NA,NA,2020-05-29,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"March 27, 2020",Actual,2020-03-27,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"October 6, 2020",Anticipated,2020-10-06,NA,Interventional,NA,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Recruiting,NA,Phase 4,200,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-07T08:43:03Z,2020-06-07T08:43:03Z
NCT04339816,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-06,NA,NA,2020-06-03,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 13, 2020",Actual,2020-05-13,June 2020,2020-06-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,AZIQUINE-ICU,,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial,Recruiting,NA,Phase 3,240,Anticipated,"Charles University, Czech Republic",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,within 6 months of study completion,NA,http://mendeley.com,Yes,Deidentified record-level data will be shared in a public database,2020-06-08T08:32:32Z,2020-06-08T08:32:32Z
NCT04384380,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-10,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Recruiting,NA,Phase 4,45,Anticipated,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2020-06-01T09:23:41Z,2020-06-01T09:23:41Z
NCT04364893,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-25,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-25,2020-04-28,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,BRACE-CORONA,,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial,Recruiting,NA,N/A,500,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:06Z,2020-06-01T09:26:06Z
NCT04361552,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"May 30, 2020",Anticipated,2020-05-30,April 2020,2020-04-30,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,NA,,Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),"Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial",Recruiting,NA,Phase 3,180,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.",2020-06-01T09:26:33Z,2020-06-01T09:26:33Z
NCT04353674,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-06,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"January 1, 2021",Anticipated,2021-01-01,"July 28, 2020",Anticipated,2020-07-28,NA,Interventional,NA,,Modulation of Hyperinflammation in COVID-19,Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients,Recruiting,NA,Phase 1,40,Anticipated,Lawson Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:35Z,2020-06-01T09:27:35Z
NCT04352933,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-11,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,PROLIFIC ChemoprophylaxisTrial (COVID-19),ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial),Recruiting,NA,Phase 3,1000,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:40Z,2020-06-01T09:27:40Z
NCT04347031,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-22,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19","Active, not recruiting",NA,Phase 2/Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:28Z,2020-06-01T09:28:28Z
NCT04346147,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-07,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,Covid-19HUF,,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,"Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia",Recruiting,NA,Phase 2,165,Anticipated,Hospital Universitario de Fuenlabrada,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:35Z,2020-06-01T09:28:35Z
NCT04345848,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-28,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVID-HEP,,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,"Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Randomized, Open-label Clinical Trial",Recruiting,NA,Phase 3,200,Anticipated,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:36Z,2020-06-01T09:28:36Z
NCT04345614,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-01,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia,A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients With Severe COVID-19 Pneumonia,Recruiting,NA,Phase 2,120,Anticipated,"CalciMedica, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:38Z,2020-06-01T09:28:38Z
NCT04344210,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 20, 2020",Anticipated,2020-08-20,NA,Interventional,NA,,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Enrolling by invitation,NA,N/A,149,Anticipated,Federal University of Rio Grande do Sul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:28:48Z,2020-06-01T09:28:48Z
NCT04342169,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,Recruiting,NA,Phase 2,400,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:03Z,2020-06-01T09:29:03Z
NCT04341493,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-22,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome,Recruiting,NA,Phase 4,86,Anticipated,Materno-Perinatal Hospital of the State of Mexico,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After finishing the study.,Requested by the journal or after publication if any researcher in the world express interest if the information of this survey.,NA,Yes,"If the final selected medical journal to send the paper of our research request it, we will add the full database of the studied population.",2020-06-01T09:29:07Z,2020-06-01T09:29:07Z
NCT04341441,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-05,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,WHIP COVID-19,,Will Hydroxychloroquine Impede or Prevent COVID-19,Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study,Recruiting,NA,Phase 3,3000,Anticipated,Henry Ford Health System,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:08Z,2020-06-01T09:29:08Z
NCT04341415,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-12,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,SOS-COVID19,,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.,Recruiting,NA,N/A,60,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:08Z,2020-06-01T09:29:08Z
NCT04341389,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:08Z,2020-06-01T09:29:08Z
NCT04341038,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-08,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,TACROVID,,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19,Recruiting,NA,Phase 3,84,Anticipated,Hospital Universitari de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:10Z,2020-06-01T09:29:10Z
NCT04340050,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-05-13,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,"Active, not recruiting",NA,Early Phase 1,10,Actual,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2020-06-01T09:29:23Z,2020-06-01T09:29:23Z
NCT04339426,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-17,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,"Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection",Recruiting,NA,Phase 2,25,Anticipated,HonorHealth Research Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:28Z,2020-06-01T09:29:28Z
NCT04338958,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-07,NA,NA,2020-04-29,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,RuxCoFlam,,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Recruiting,NA,Phase 2,200,Anticipated,University of Jena,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:29:31Z,2020-06-01T09:29:31Z
NCT04341922,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-07,NA,NA,2020-05-29,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"September 10, 2021",Anticipated,2021-09-10,"September 10, 2020",Anticipated,2020-09-10,NA,Interventional,NA,,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial,Recruiting,NA,N/A,670,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:43:00Z,2020-06-07T08:43:00Z
NCT04358081,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-19,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"July 24, 2020",Anticipated,2020-07-24,"June 25, 2020",Anticipated,2020-06-25,NA,Interventional,NA,,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Recruiting,NA,Phase 3,444,Anticipated,Novartis,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-06-01T09:26:59Z,2020-06-01T09:26:59Z
NCT04350580,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-21,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,ICAR,,Polyvalent Immunoglobulin in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Recruiting,NA,Phase 3,138,Anticipated,Centre Hospitalier St Anne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:57Z,2020-06-01T09:27:57Z
NCT04348383,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"August 8, 2020",Anticipated,2020-08-08,"July 8, 2020",Anticipated,2020-07-08,NA,Interventional,DEFACOVID,,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,"Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome",Recruiting,NA,Phase 2,120,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:14Z,2020-06-01T09:28:14Z
NCT04347681,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-18,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"April 18, 2020",Actual,2020-04-18,April 2020,2020-04-30,"April 11, 2021",Anticipated,2021-04-11,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,NA,Phase 2,40,Anticipated,King Fahad Specialist Hospital Dammam,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:24Z,2020-06-01T09:28:24Z
NCT04346693,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-22,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),"Active, not recruiting",NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:30Z,2020-06-01T09:28:30Z
NCT04346420,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Recruiting,NA,N/A,15,Anticipated,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:32Z,2020-06-01T09:28:32Z
NCT04345653,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-14,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 8, 2022",Anticipated,2022-04-08,"April 8, 2021",Anticipated,2021-04-08,NA,Interventional,NA,,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Enrolling by invitation,NA,Phase 2,45,Anticipated,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:38Z,2020-06-01T09:28:38Z
NCT04344587,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-11,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,APPEX-19,,Awake Prone Position for Early Hypoxemia in COVID-19,Awake Prone Position for Early Hypoxemia in COVID-19,Enrolling by invitation,NA,N/A,560,Anticipated,Boston University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:46Z,2020-06-01T09:28:46Z
NCT04344457,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-28,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,COVID-19,,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms",Recruiting,NA,Phase 1/Phase 2,80,Anticipated,"Perseverance Research Center, LLC",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:47Z,2020-06-01T09:28:47Z
NCT04344236,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"May 9, 2020",Anticipated,2020-05-09,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,"A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19",Recruiting,NA,Phase 2,48,Anticipated,NYU Langone Health,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests should be directed to scott.rickert@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-06-01T09:28:48Z,2020-06-01T09:28:48Z
NCT04344106,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 1, 2020",Anticipated,2020-05-01,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,ProCov,,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,N/A,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:49Z,2020-06-01T09:28:49Z
NCT04343768,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-02,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Interventional,COVIFERON,,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2020-06-01T09:28:52Z,2020-06-01T09:28:52Z
NCT04343755,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection,Recruiting,NA,Phase 2,55,Anticipated,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:52Z,2020-06-01T09:28:52Z
NCT04343261,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"April 1, 2021",Anticipated,2021-04-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Enrolling by invitation,NA,Phase 2,45,Anticipated,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:56Z,2020-06-01T09:28:56Z
NCT04342728,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Enrolling by invitation,NA,N/A,520,Anticipated,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:59Z,2020-06-01T09:28:59Z
NCT04342663,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-05-18,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Recruiting,NA,Phase 2,152,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:00Z,2020-06-01T09:29:00Z
NCT04342221,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"March 29, 2020",Actual,2020-03-29,March 2020,2020-03-31,February 2022,Anticipated,2022-02-28,March 2021,Anticipated,2021-03-31,NA,Interventional,COV-HCQ,,Hydroxychloroquine for COVID-19,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19,Recruiting,NA,Phase 3,220,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:29:02Z,2020-06-01T09:29:02Z
NCT04341207,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,ONCOVID,,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients,Recruiting,NA,Phase 2,1000,Anticipated,"Gustave Roussy, Cancer Campus, Grand Paris",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:29:09Z,2020-06-01T09:29:09Z
NCT04343248,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-08,NA,NA,2020-06-01,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",Recruiting,NA,Phase 3,800,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:27Z,2020-06-08T08:32:27Z
NCT04341142,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-08,NA,NA,2020-06-02,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"September 9, 2020",Anticipated,2020-09-09,"September 9, 2020",Anticipated,2020-09-09,NA,Interventional,COVID-SER,,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,NA,N/A,130,Anticipated,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:30Z,2020-06-08T08:32:30Z
NCT04353037,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-21,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"June 15, 2021",Anticipated,2021-06-15,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19,Recruiting,NA,Phase 2,850,Anticipated,UnitedHealth Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,1 year,NA,NA,Yes,Data will be collected and managed by Optumcare and UnitedHealth Group Research & Development. Redacted/aggregate data will be shared with the University Of Penn using approved data sharing protocols.,2020-06-01T09:27:39Z,2020-06-01T09:27:39Z
NCT04351906,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-05-04,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 3, 2020",Actual,2020-05-03,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,NA,N/A,20,Anticipated,University of Giessen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:48Z,2020-06-01T09:27:48Z
NCT04347980,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-16,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DHYSCO,,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,"Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial",Recruiting,NA,Phase 3,122,Anticipated,Centre Chirurgical Marie Lannelongue,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Beginning 3 months and ending 24 months following article publication,Researchers who provide a methodologically sound and proposal. Data are available for 24 months and request should be addressed by email,NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2020-06-01T09:28:19Z,2020-06-01T09:28:19Z
NCT04346615,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-05-18,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,"BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",Recruiting,NA,Phase 2/Phase 3,120,Anticipated,"Biohaven Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:31Z,2020-06-01T09:28:31Z
NCT04346589,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-05-07,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,N/A,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:31Z,2020-06-01T09:28:31Z
NCT04344730,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 10, 2020",Actual,2020-04-10,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVIDICUS,,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS,Recruiting,NA,N/A,550,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:45Z,2020-06-01T09:28:45Z
NCT04344431,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-20,2020-04-11,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Interventional,OHB10cov,,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:47Z,2020-06-01T09:28:47Z
NCT04344080,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,CYTOCOV-19,,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Recruiting,NA,N/A,24,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:49Z,2020-06-01T09:28:49Z
NCT04344041,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-05-04,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,NA,Phase 3,260,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:49Z,2020-06-01T09:28:49Z
NCT04344015,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-05-08,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 13, 2020",Actual,2020-04-13,May 2020,2020-05-31,"April 12, 2021",Anticipated,2021-04-12,"April 12, 2021",Anticipated,2021-04-12,NA,Interventional,NA,,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Recruiting,NA,N/A,2000,Anticipated,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:50Z,2020-06-01T09:28:50Z
NCT04343989,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-05-04,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"March 31, 2020",Actual,2020-03-31,May 2020,2020-05-31,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,90,Anticipated,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-06-01T09:28:50Z,2020-06-01T09:28:50Z
NCT04343963,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-13,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,PISCO,,Pyridostigmine in Severe SARS-CoV-2 Infection,Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:50Z,2020-06-01T09:28:50Z
NCT04343729,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-09,NA,NA,2020-04-29,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 18, 2020",Actual,2020-04-18,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,MetCOVID,,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Recruiting,NA,Phase 2,420,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2020-06-01T09:28:52Z,2020-06-01T09:28:52Z
NCT04348513,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-09,NA,NA,2020-05-29,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"May 2, 2021",Anticipated,2021-05-02,NA,Interventional,Thy-Support,,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support),Recruiting,NA,Phase 2,60,Anticipated,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:42:49Z,2020-06-07T08:42:49Z
NCT04345692,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-09,NA,NA,2020-06-01,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"March 26, 2020",Actual,2020-03-26,June 2020,2020-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,OAHU-COVID19,,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 3,350,Anticipated,Queen's Medical Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:25Z,2020-06-08T08:32:25Z
NCT04390178,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,"Active, not recruiting",NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,We will be sharing data but data the management plan is being designed.,2020-06-01T09:23:00Z,2020-06-01T09:23:00Z
NCT04351724,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-04-21,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,ACOVACT,,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Medical University of Vienna,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences,2020-06-01T09:27:49Z,2020-06-01T09:27:49Z
NCT04348929,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-04-20,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"November 1, 2021",Anticipated,2021-11-01,"August 16, 2021",Anticipated,2021-08-16,NA,Interventional,CONFINE,,Birth Experience During COVID-19 Confinement,Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care),Recruiting,NA,N/A,600,Anticipated,"Central Hospital, Nancy, France",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:09Z,2020-06-01T09:28:09Z
NCT04345991,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-05-19,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"June 1, 2020",Anticipated,2020-06-01,"May 15, 2020",Anticipated,2020-05-15,NA,Interventional,CORIPLASM,,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:36Z,2020-06-01T09:28:36Z
NCT04345549,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"February 26, 2020",Actual,2020-02-26,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:38Z,2020-06-01T09:28:38Z
NCT04344535,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-04-15,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma vs. Standard Plasma for COVID-19,Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection,Enrolling by invitation,NA,Phase 1/Phase 2,500,Anticipated,Stony Brook University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:46Z,2020-06-01T09:28:46Z
NCT04344444,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"December 10, 2021",Anticipated,2021-12-10,"April 10, 2021",Anticipated,2021-04-10,NA,Interventional,RCT,,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial,Recruiting,NA,Phase 3,600,Anticipated,LCMC Health,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:47Z,2020-06-01T09:28:47Z
NCT04344288,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-10,NA,NA,2020-04-16,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,CORTI-Covid,,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Recruiting,NA,Phase 2,304,Anticipated,Hospices Civils de Lyon,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:48Z,2020-06-01T09:28:48Z
NCT04344561,"ClinicalTrials.gov processed this data on June 01, 2020",2020-04-10,NA,NA,2020-05-26,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"June 20, 2020",Anticipated,2020-06-20,April 2020,2020-04-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,UPSAT,,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT),Recruiting,NA,N/A,70,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Access to IPD on reasonable request,2020-06-02T08:29:18Z,2020-06-02T08:29:18Z
NCT04342897,"ClinicalTrials.gov processed this data on June 01, 2020",2020-04-10,NA,NA,2020-05-27,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"April 20, 2020",Actual,2020-04-20,"May 1, 2020",2020-05-01,"July 16, 2020",Anticipated,2020-07-16,"June 12, 2020",Anticipated,2020-06-12,NA,Interventional,NA,,A Study of LY3127804 in Participants With COVID-19,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Recruiting,NA,Phase 2,200,Anticipated,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2020-06-02T08:29:20Z,2020-06-02T08:29:20Z
NCT04345289,"ClinicalTrials.gov processed this data on June 02, 2020",2020-04-10,NA,NA,2020-05-27,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,CCAP,,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multi-stage, 6-armed Placebo-controlled Trial in the Framework of an Adaptive Trial Platform",Recruiting,NA,Phase 3,1500,Anticipated,Hvidovre University Hospital,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-03T08:31:31Z,2020-06-03T08:31:31Z
NCT04345276,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-10,NA,NA,2020-06-01,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-07T08:42:55Z,2020-06-07T08:42:55Z
NCT04344600,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-10,NA,NA,2020-05-29,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,PROTECT,,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection,Recruiting,NA,Phase 2,164,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:42:56Z,2020-06-07T08:42:56Z
NCT04349410,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-11,NA,NA,2020-04-16,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,"November 11, 2020",Anticipated,2020-11-11,"October 11, 2020",Anticipated,2020-10-11,NA,Interventional,FMTVDM,,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Enrolling by invitation,NA,Phase 2/Phase 3,500,Anticipated,The Camelot Foundation,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2020-06-01T09:28:05Z,2020-06-01T09:28:05Z
NCT04348305,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-11,NA,NA,2020-05-11,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"December 30, 2021",Anticipated,2021-12-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,COVID STEROID,,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,Recruiting,NA,Phase 3,1000,Anticipated,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2020-06-01T09:28:15Z,2020-06-01T09:28:15Z
NCT04347538,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-11,NA,NA,2020-05-12,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Recruiting,NA,N/A,90,Anticipated,Vanderbilt University Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:25Z,2020-06-01T09:28:25Z
NCT04347382,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-11,NA,NA,2020-05-13,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 20, 2020",Anticipated,2020-05-20,May 2020,2020-05-31,"July 30, 2020",Anticipated,2020-07-30,"July 25, 2020",Anticipated,2020-07-25,NA,Interventional,HNS-COVID-PK,,Honey & Nigella Sativa-COVID-Pakistan Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Lahore, Pakistan",Recruiting,NA,Phase 3,30,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:26Z,2020-06-01T09:28:26Z
NCT04349371,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-12,NA,NA,2020-04-17,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Saved From COVID-19,Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID,Recruiting,NA,Phase 2,350,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:06Z,2020-06-01T09:28:06Z
NCT04346355,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-12,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,398,Anticipated,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:32Z,2020-06-01T09:28:32Z
NCT04359251,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"March 25, 2020",Actual,2020-03-25,"March 25, 2020",Actual,2020-03-25,NA,Interventional,NA,,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,N/A,20,Actual,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:50Z,2020-06-01T09:26:50Z
NCT04355728,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-27,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 25, 2020",Actual,2020-04-25,April 2020,2020-04-30,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,24,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:17Z,2020-06-01T09:27:17Z
NCT04350281,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-17,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"July 31, 2022",Anticipated,2022-07-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Recruiting,NA,Phase 2,80,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:00Z,2020-06-01T09:28:00Z
NCT04348864,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Antibody Self-testing Using Virtual Point-of-care,Assessment of COVID-19 IgM/IgG Self-testing Using Virtual Point-of-care,Recruiting,NA,N/A,100,Anticipated,Neuroganics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:09Z,2020-06-01T09:28:09Z
NCT04348695,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"May 13, 2020",Anticipated,2020-05-13,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,Ruxo-Sim-20,,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:11Z,2020-06-01T09:28:11Z
NCT04348656,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-05-19,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 11, 2020",Anticipated,2020-05-11,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,CONCOR-1,,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1),Recruiting,NA,Phase 3,1200,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:11Z,2020-06-01T09:28:11Z
NCT04346667,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-30,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"June 30, 2021",Anticipated,2021-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,PEACE,,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:30Z,2020-06-01T09:28:30Z
NCT04346017,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Recruiting,NA,N/A,200,Anticipated,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:35Z,2020-06-01T09:28:35Z
NCT04357340,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-13,NA,NA,2020-05-30,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 2, 2020",Actual,2020-04-02,May 2020,2020-05-31,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,N/A,40,Actual,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2020-06-07T08:42:32Z,2020-06-07T08:42:32Z
NCT04348500,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-13,NA,NA,2020-06-03,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"April 24, 2020",Actual,2020-04-24,June 2020,2020-06-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,Recruiting,NA,Phase 2,60,Anticipated,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:32:22Z,2020-06-08T08:32:22Z
NCT04347239,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-13,NA,NA,2020-06-01,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"April 15, 2020",Actual,2020-04-15,June 2020,2020-06-30,"April 1, 2021",Anticipated,2021-04-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,390,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:32:24Z,2020-06-08T08:32:24Z
NCT04382391,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-12,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"December 30, 2020",Anticipated,2020-12-30,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,SAVIORII,,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)",Recruiting,NA,N/A,20,Anticipated,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:54Z,2020-06-01T09:23:54Z
NCT04361916,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,Mon-Covid,,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Recruiting,NA,N/A,425,Anticipated,Mario Negri Institute for Pharmacological Research,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,data will be available from the study sponsor upon legitimate request,2020-06-01T09:26:31Z,2020-06-01T09:26:31Z
NCT04357808,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-20,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,SARCOVID,,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:01Z,2020-06-01T09:27:01Z
NCT04357106,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COPLA,,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,NA,Phase 2,10,Anticipated,Centro de HematologÃ­a y Medicina Interna,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:05Z,2020-06-01T09:27:05Z
NCT04355143,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-19,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"April 25, 2021",Anticipated,2021-04-25,"April 25, 2021",Anticipated,2021-04-25,NA,Interventional,COLHEART-19,,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),"Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)",Recruiting,NA,Phase 2,150,Anticipated,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:24Z,2020-06-01T09:27:24Z
NCT04354831,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-11,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"May 1, 2023",Anticipated,2023-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection",Recruiting,NA,Phase 2,131,Anticipated,Medical College of Wisconsin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:26Z,2020-06-01T09:27:26Z
NCT04354610,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-05,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"October 18, 2020",Anticipated,2020-10-18,"July 18, 2020",Anticipated,2020-07-18,NA,Interventional,Nancy-CovH-AKI,,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection,Recruiting,NA,N/A,57,Anticipated,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:27Z,2020-06-01T09:27:27Z
NCT04353596,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-21,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"May 15, 2022",Anticipated,2022-05-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,ACEI-COVID,,Stopping ACE-inhibitors in COVID-19,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 4,208,Anticipated,Medical University Innsbruck,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:36Z,2020-06-01T09:27:36Z
NCT04352608,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-26,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 13, 2020",Anticipated,2020-12-13,"August 13, 2020",Anticipated,2020-08-13,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years",Recruiting,NA,Phase 1/Phase 2,744,Anticipated,"Sinovac Biotech Co., Ltd",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:42Z,2020-06-01T09:27:42Z
NCT04351763,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"April 10, 2021",Anticipated,2021-04-10,"March 2, 2021",Anticipated,2021-03-02,NA,Interventional,ReCOVery-SIRIO,,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,NA,Phase 2/Phase 3,804,Anticipated,Nicolaus Copernicus University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:49Z,2020-06-01T09:27:49Z
NCT04351620,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:50Z,2020-06-01T09:27:50Z
NCT04351542,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,"April 12, 2020",Actual,2020-04-12,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,N/A,32,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:50Z,2020-06-01T09:27:50Z
NCT04351191,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-29,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,PRECISE,,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:52Z,2020-06-01T09:27:52Z
NCT04350736,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-20,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Recruiting,NA,Phase 1,54,Anticipated,Theravance Biopharma,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2020-06-01T09:27:56Z,2020-06-01T09:27:56Z
NCT04350684,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 22, 2020",Anticipated,2020-04-22,NA,Interventional,UAIIC,,Umifenovir in Hospitalized COVID-19 Patients,"Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,There is no further information.,2020-06-01T09:27:57Z,2020-06-01T09:27:57Z
NCT04350671,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,IB1aIC,,Interferon Beta 1a in Hospitalized COVID-19 Patients,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,There is no further information.,2020-06-01T09:27:57Z,2020-06-01T09:27:57Z
NCT04350593,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,DARE-19,,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Recruiting,NA,Phase 3,900,Anticipated,Saint Luke's Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:57Z,2020-06-01T09:27:57Z
NCT04350320,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-02,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"November 20, 2020",Anticipated,2020-11-20,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,COL-COVID,,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Recruiting,NA,Phase 3,102,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:59Z,2020-06-01T09:27:59Z
NCT04350073,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-20,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Recruiting,NA,N/A,120,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:01Z,2020-06-01T09:28:01Z
NCT04349228,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-03,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-03,2020-05-06,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"July 15, 2020",Anticipated,2020-07-15,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,COVID_2Pro,,Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals,"Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study",Recruiting,NA,Phase 3,530,Anticipated,Abderrahmane Mami Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:07Z,2020-06-01T09:28:07Z
NCT04349098,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-06,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Recruiting,NA,Phase 2,230,Anticipated,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:28:08Z,2020-06-01T09:28:08Z
NCT04348435,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-04-28,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 23, 2020",Anticipated,2020-04-23,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Enrolling by invitation,NA,Phase 2,100,Anticipated,Hope Biosciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:28:14Z,2020-06-01T09:28:14Z
NCT04347915,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-14,NA,NA,2020-05-07,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"May 6, 2020",Actual,2020-05-06,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,"The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19",Recruiting,NA,Phase 2,60,Anticipated,Bukwang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:28:19Z,2020-06-01T09:28:19Z
NCT04351581,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-14,NA,NA,2020-06-04,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"May 18, 2020",Actual,2020-05-18,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,RASCOVID-19,,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,NA,N/A,215,Anticipated,"University Hospital, Gentofte, Copenhagen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:19Z,2020-06-08T08:32:19Z
NCT04346446,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-14,NA,NA,2020-06-04,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:32:25Z,2020-06-08T08:32:25Z
NCT04357327,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-04-22,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Recruiting,NA,N/A,100,Anticipated,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2020-06-01T09:27:04Z,2020-06-01T09:27:04Z
NCT04356534,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-05-12,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"April 19, 2020",Actual,2020-04-19,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Recruiting,NA,N/A,40,Anticipated,Royal College of Surgeons in Ireland - Medical University of Bahrain,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.
Data will be collected in the case report form to allow for cross referencing to check validity.
Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2020-06-01T09:27:10Z,2020-06-01T09:27:10Z
NCT04355897,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-05-18,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,CoVID-19 Plasma in Treatment of COVID-19 Patients,Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease,Recruiting,NA,Early Phase 1,100,Anticipated,The Christ Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:15Z,2020-06-01T09:27:15Z
NCT04355637,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-05-05,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,"October 18, 2020",Anticipated,2020-10-18,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Recruiting,NA,Phase 4,300,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:18Z,2020-06-01T09:27:18Z
NCT04355026,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-04-18,2020-04-18,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 4,90,Anticipated,General and Teaching Hospital Celje,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:25Z,2020-06-01T09:27:25Z
NCT04351516,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-05-26,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVID65plus,,Test and Treat COVID 65plus+,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients,Recruiting,NA,Phase 2/Phase 3,350,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:27:50Z,2020-06-01T09:27:50Z
NCT04351152,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-15,NA,NA,2020-05-26,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia",Recruiting,NA,Phase 3,238,Anticipated,"Humanigen, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:27:53Z,2020-06-01T09:27:53Z
NCT04351243,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-15,NA,NA,2020-05-28,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE).,"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE).",Recruiting,NA,Phase 2,270,Anticipated,Kinevant Sciences GmbH,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-06T08:49:53Z,2020-06-06T08:49:53Z
NCT04355364,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-15,NA,NA,2020-05-29,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"April 21, 2020",Actual,2020-04-21,May 2020,2020-05-31,"August 21, 2020",Anticipated,2020-08-21,"August 21, 2020",Anticipated,2020-08-21,NA,Interventional,COVIDORNASE,,Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE),Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 3,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-06T08:49:46Z,2020-06-06T08:49:46Z
NCT04367662,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-04-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COVID'HEMOS,,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Recruiting,NA,N/A,100,Anticipated,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:45Z,2020-06-01T09:25:45Z
NCT04361344,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-05-19,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 19, 2020",Actual,2020-05-19,May 2020,2020-05-31,"January 19, 2021",Anticipated,2021-01-19,"January 19, 2021",Anticipated,2021-01-19,NA,Interventional,MARNEVO-Covid,,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid,Recruiting,NA,N/A,30,Anticipated,Centre Hospitalier de PAU,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:36Z,2020-06-01T09:26:36Z
NCT04359264,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-05-25,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"May 29, 2020",Anticipated,2020-05-29,NA,Interventional,DISTANSE COVID,,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT),"Active, not recruiting",NA,N/A,392,Actual,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:26:50Z,2020-06-01T09:26:50Z
NCT04358939,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-04-28,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"November 24, 2020",Anticipated,2020-11-24,"November 10, 2020",Anticipated,2020-11-10,NA,Interventional,NA,,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome,Recruiting,NA,N/A,248,Anticipated,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:52Z,2020-06-01T09:26:52Z
NCT04358549,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-04-24,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-24,2020-04-28,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19",Recruiting,NA,Phase 2,50,Anticipated,"Fujifilm Pharmaceuticals U.S.A., Inc.",,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:55Z,2020-06-01T09:26:55Z
NCT04354870,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-04-20,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Recruiting,NA,Phase 2,350,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Study internal to NYU at this time,2020-06-01T09:27:26Z,2020-06-01T09:27:26Z
NCT04354259,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-05-13,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,ILIAD,,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",Recruiting,NA,Phase 2,140,Anticipated,"University Health Network, Toronto",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:30Z,2020-06-01T09:27:30Z
NCT04353206,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-05-12,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19,Recruiting,NA,Early Phase 1,60,Anticipated,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:38Z,2020-06-01T09:27:38Z
NCT04352751,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-16,NA,NA,2020-05-13,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 1, 2020",Actual,2020-05-01,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,NA,N/A,2000,Anticipated,Hilton Pharma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:41Z,2020-06-01T09:27:41Z
NCT04354428,"ClinicalTrials.gov processed this data on June 01, 2020",2020-04-16,NA,NA,2020-05-26,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Treatment for COVID-19 in High-Risk Adult Outpatients,Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial,Recruiting,NA,Phase 2/Phase 3,630,Anticipated,University of Washington,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-06-02T08:29:09Z,2020-06-02T08:29:09Z
NCT04361838,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-16,NA,NA,2020-06-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,The COVID-19 ICU PRAYER Study,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection,Recruiting,NA,N/A,1000,Anticipated,Kansas City Heart Rhythm Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:06Z,2020-06-08T08:32:06Z
NCT04364009,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-17,NA,NA,2020-05-13,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"September 24, 2020",Anticipated,2020-09-24,"September 10, 2020",Anticipated,2020-09-10,NA,Interventional,ANACONDA,,Anakinra for COVID-19 Respiratory Symptoms,"Efficacy and Safety of ANAkinra During Adult "" COVID-19 "" With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial",Recruiting,NA,Phase 3,240,Anticipated,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:12Z,2020-06-01T09:26:12Z
NCT04363853,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-17,NA,NA,2020-04-23,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Tocilizumab Treatment in Patients With COVID-19,Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab,Recruiting,NA,Phase 2,200,Anticipated,Instituto Nacional de Cancerologia de Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data wil be avaible in july 2020,NA,NA,Yes,NA,2020-06-01T09:26:16Z,2020-06-01T09:26:16Z
NCT04361942,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-17,NA,NA,2020-04-28,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVID_MSV,,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),"Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)",Recruiting,NA,Phase 2,24,Anticipated,Red de Terapia Celular,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:31Z,2020-06-01T09:26:31Z
NCT04357782,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-17,NA,NA,2020-04-20,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,AVoCaDO,,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:01Z,2020-06-01T09:27:01Z
NCT04356690,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-17,NA,NA,2020-05-07,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Etoposide in Patients With COVID-19 Infection,"A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection",Recruiting,NA,Phase 2,64,Anticipated,Boston Medical Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:09Z,2020-06-01T09:27:09Z
NCT04355247,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-17,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,NA,Phase 2,20,Anticipated,Auxilio Mutuo Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:27:23Z,2020-06-01T09:27:23Z
NCT04373044,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-17,NA,NA,2020-05-30,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19,Recruiting,NA,Phase 2,144,Anticipated,University of Southern California,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-07T08:42:10Z,2020-06-07T08:42:10Z
NCT04356482,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-17,NA,NA,2020-06-03,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,COPLASCOV19,,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:13Z,2020-06-08T08:32:13Z
NCT04355936,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-17,NA,NA,2020-06-01,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 19, 2020",Actual,2020-05-19,June 2020,2020-06-30,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Recruiting,NA,Phase 2,400,Anticipated,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:14Z,2020-06-08T08:32:14Z
NCT04377308,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-18,NA,NA,2020-05-04,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"October 20, 2021",Anticipated,2021-10-20,"April 20, 2021",Anticipated,2021-04-20,NA,Interventional,NA,,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,NA,Phase 4,2000,Anticipated,University of Toledo Health Science Campus,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:32Z,2020-06-01T09:24:32Z
NCT04357730,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-18,NA,NA,2020-06-01,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 14, 2020",Actual,2020-05-14,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial,Recruiting,NA,Phase 2,60,Anticipated,Denver Health and Hospital Authority,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,A de-identified dataset will be made available to other investigators who may submit proposals to the PI for additional analyses or validation.,2020-06-08T08:32:11Z,2020-06-08T08:32:11Z
NCT04376034,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-19,NA,NA,2020-05-01,2020-05-01,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-06,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma,Recruiting,NA,Phase 3,240,Anticipated,West Virginia University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:41Z,2020-06-01T09:24:41Z
NCT04358614,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 7, 2020",Actual,2020-04-07,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:54Z,2020-06-01T09:26:54Z
NCT04368845,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-05-19,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 11, 2020",Actual,2020-05-11,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,ATHLOS,,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,"A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study",Recruiting,NA,N/A,100,Anticipated,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:37Z,2020-06-01T09:25:37Z
NCT04368156,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,SAVIOR,,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)",Recruiting,NA,N/A,90,Anticipated,Hospital ClÃ­nico Universitario de Valencia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:25:42Z,2020-06-01T09:25:42Z
NCT04366063,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-04-29,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"December 10, 2020",Anticipated,2020-12-10,"June 6, 2020",Anticipated,2020-06-06,NA,Interventional,NA,,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Royan Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,6 months after publication,Researchers and clinicians,NA,Yes,NA,2020-06-01T09:25:57Z,2020-06-01T09:25:57Z
NCT04362332,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"May 14, 2021",Anticipated,2021-05-14,"April 14, 2021",Anticipated,2021-04-14,NA,Interventional,ARCHAIC,,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Recruiting,NA,Phase 4,950,Anticipated,UMC Utrecht,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,12 months,NA,NA,Yes,NA,2020-06-01T09:26:28Z,2020-06-01T09:26:28Z
NCT04362085,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-05-13,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Recruiting,NA,Phase 3,462,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:30Z,2020-06-01T09:26:30Z
NCT04359797,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-04-27,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,June 2021,Anticipated,2021-06-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Enrolling by invitation,NA,N/A,300,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2020-06-01T09:26:47Z,2020-06-01T09:26:47Z
NCT04359537,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-05-16,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"August 25, 2020",Anticipated,2020-08-25,NA,Interventional,CHEER,,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel,Recruiting,NA,Phase 2,200,Anticipated,Shaheed Zulfiqar Ali Bhutto Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:48Z,2020-06-01T09:26:48Z
NCT04359277,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-04-29,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"April 16, 2021",Anticipated,2021-04-16,"April 16, 2021",Anticipated,2021-04-16,NA,Interventional,NA,,A Randomized Trial of Anticoagulation Strategies in COVID-19,A Randomized Trial of Anticoagulation Strategies in COVID-19,Recruiting,NA,Phase 3,1000,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests may be directed to: jeffrey.berger@nyumc.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: jeffrey.berger@nyumc.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-06-01T09:26:50Z,2020-06-01T09:26:50Z
NCT04357990,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-05-04,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 1, 2020",Anticipated,2020-05-01,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,KONS-COVID-19,,Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19,"Use of a Medical Device, Kerecis Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa",Recruiting,NA,N/A,81,Anticipated,Kerecis Ltd.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:59Z,2020-06-01T09:26:59Z
NCT04357366,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-20,NA,NA,2020-04-23,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"April 15, 2022",Anticipated,2022-04-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,SAVE,,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial",Recruiting,NA,Phase 2,100,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:27:03Z,2020-06-01T09:27:03Z
NCT04358068,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-20,NA,NA,2020-05-29,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"March 5, 2021",Anticipated,2021-03-05,"October 9, 2020",Anticipated,2020-10-09,NA,Interventional,NA,,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",Recruiting,NA,Phase 2,2000,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2020-06-06T08:49:41Z,2020-06-06T08:49:41Z
NCT04374084,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-20,NA,NA,2020-06-03,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"May 10, 2020",Actual,2020-05-10,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial,Recruiting,NA,N/A,60,Anticipated,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,It depends.,It depends.,NA,Yes,Individual participant data are available on reasonable request. You can send e-mail to us if you have any question.,2020-06-08T08:31:50Z,2020-06-08T08:31:50Z
NCT04359680,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-20,NA,NA,2020-06-01,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 13, 2020",Actual,2020-05-13,June 2020,2020-06-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers,"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers",Recruiting,NA,Phase 3,800,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:08Z,2020-06-08T08:32:08Z
NCT04359901,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-20,NA,NA,2020-06-02,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 10, 2020",Actual,2020-04-10,June 2020,2020-06-30,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,Sarilumab for Patients With Moderate COVID-19 Disease,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design,Recruiting,NA,Phase 2,120,Anticipated,VA Boston Healthcare System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within one year of primary publication.,"Consistent with VA Privacy, Regulatory and IT requirements and VHA Handbook 1200.12",NA,Yes,"Digital data underlying primary scientific publications will be held as part of a data sharing resource. Study data held for this purpose may include data, data content, format, and organization. The data may contain but are not limited to individually identifiable information, other PHI, and study codes. The data may be available to the public and other VA and non-VA researchers under certain conditions and consistent with the informed consent and CSP policy that prioritize protecting participants' privacy and confidentiality to the fullest extent possible. A detailed plan will be developed in accordance with current technology, infrastructure, best practices, and policies and procedures in place at the time of oversight committee reviews (e.g., Privacy Board, Information Security, and Information Technology standards). The plan will include how data will be discovered, retrieved, analyzed, and managed and will note the materials that are available in machine-readable formats.",2020-06-08T08:32:07Z,2020-06-08T08:32:07Z
NCT04358003,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-20,NA,NA,2020-06-01,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,"December 1, 2020",Anticipated,2020-12-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,Plasma Adsorption in Patients With Confirmed COVID-19,Plasma Adsorption in Patients With Confirmed COVID-19 Infection,Recruiting,NA,N/A,2000,Anticipated,Marker Therapeutics AG,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:11Z,2020-06-08T08:32:11Z
NCT04362176,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-04-29,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-04,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,PassItOnII,,Passive Immunity Trial of Nashville II for COVID-19,"A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,500,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:29Z,2020-06-01T09:26:29Z
NCT04361526,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CytokCOVID19,,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19),Recruiting,NA,N/A,40,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:33Z,2020-06-01T09:26:33Z
NCT04359862,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-04-28,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"September 16, 2020",Anticipated,2020-09-16,"August 16, 2020",Anticipated,2020-08-16,NA,Interventional,SEVO-COVID19,,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,NA,Phase 4,50,Anticipated,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:46Z,2020-06-01T09:26:46Z
NCT04359810,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-04-28,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Plasma Therapy of COVID-19 in Critically Ill Patients,"A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Recruiting,NA,Phase 2,105,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:46Z,2020-06-01T09:26:46Z
NCT04359329,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Estrogen Patch for COVID-19 Symptoms,Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients,Recruiting,NA,Phase 2,110,Anticipated,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:49Z,2020-06-01T09:26:49Z
NCT04358926,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-05-03,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-03,2020-05-05,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,HBOTCOVID19,,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Recruiting,NA,N/A,30,Anticipated,Assaf-Harofeh Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2020-06-01T09:26:52Z,2020-06-01T09:26:52Z
NCT04358783,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-21,NA,NA,2020-05-15,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"May 30, 2021",Anticipated,2021-05-30,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,COP-COVID-19,,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Recruiting,NA,Phase 2,30,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:53Z,2020-06-01T09:26:53Z
NCT04363736,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-21,NA,NA,2020-05-29,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"August 3, 2020",Anticipated,2020-08-03,"July 3, 2020",Anticipated,2020-07-03,NA,Interventional,MARIPOSA,,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2,100,Anticipated,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-06-07T08:42:22Z,2020-06-07T08:42:22Z
NCT04413864,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-21,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,DEXDO-COVID,,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,NA,N/A,50,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:30:08Z,2020-06-08T08:30:08Z
NCT04366882,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,MIA-COVID-19,,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,"Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients",Recruiting,NA,N/A,45,Anticipated,Jessa Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:52Z,2020-06-01T09:25:52Z
NCT04366089,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"March 26, 2020",Actual,2020-03-26,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,PROBIOZOVID,,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,Recruiting,NA,Phase 2,152,Anticipated,Azienda Policlinico Umberto I,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:57Z,2020-06-01T09:25:57Z
NCT04365101,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-05-22,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,CYNK001COVID,,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19),A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19,Recruiting,NA,Phase 1/Phase 2,86,Anticipated,Celularity Incorporated,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:04Z,2020-06-01T09:26:04Z
NCT04364737,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-05-05,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,"April 30, 2023",Anticipated,2023-04-30,"January 31, 2023",Anticipated,2023-01-31,NA,Interventional,NA,,Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients,Recruiting,NA,Phase 2,300,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.",2020-06-01T09:26:07Z,2020-06-01T09:26:07Z
NCT04364594,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-05-25,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"March 26, 2020",Actual,2020-03-26,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 24, 2020",Actual,2020-05-24,NA,Interventional,COVID-T,,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,"Active, not recruiting",NA,N/A,50,Anticipated,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2020-06-01T09:26:08Z,2020-06-01T09:26:08Z
NCT04361474,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-05-18,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,"May 25, 2021",Anticipated,2021-05-25,"May 18, 2020",Actual,2020-05-18,NA,Interventional,COVIDORL,,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Recruiting,NA,Phase 3,120,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:34Z,2020-06-01T09:26:34Z
NCT04361396,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-04-28,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,LAPTRANSCOV,,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Recruiting,NA,N/A,40,Anticipated,Centre Hospitalier RenÃ© Dubos,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:35Z,2020-06-01T09:26:35Z
NCT04361214,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-05-19,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Leflunomide in Mild COVID-19 Patients,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:36Z,2020-06-01T09:26:36Z
NCT04360980,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial,Recruiting,NA,Phase 2,80,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:38Z,2020-06-01T09:26:38Z
NCT04360837,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-05-19,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT),Recruiting,NA,N/A,10,Anticipated,Szeged University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:39Z,2020-06-01T09:26:39Z
NCT04360811,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-22,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COroFet,,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic by Creation and Analysis of a Biological and Tissue Collection of Pregnancy Outcomes",Recruiting,NA,N/A,3600,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:39Z,2020-06-01T09:26:39Z
NCT04373200,"ClinicalTrials.gov processed this data on June 01, 2020",2020-04-22,NA,NA,2020-05-27,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"November 25, 2020",Anticipated,2020-11-25,"November 25, 2020",Anticipated,2020-11-25,NA,Interventional,HARMONICOV,,Human Ab Response & immunoMONItoring of COVID-19 Patients,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,NA,N/A,75,Anticipated,Rennes University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-02T08:28:53Z,2020-06-02T08:28:53Z
NCT04366323,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-22,NA,NA,2020-06-04,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"April 27, 2020",Actual,2020-04-27,June 2020,2020-06-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",Recruiting,NA,Phase 1/Phase 2,26,Anticipated,Andalusian Network for Design and Translation of Advanced Therapies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:03Z,2020-06-08T08:32:03Z
NCT04366245,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-22,NA,NA,2020-06-03,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"April 23, 2020",Actual,2020-04-23,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,"Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,Andalusian Network for Design and Translation of Advanced Therapies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:32:03Z,2020-06-08T08:32:03Z
NCT04362137,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-22,NA,NA,2020-06-02,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"July 13, 2020",Anticipated,2020-07-13,"July 10, 2020",Anticipated,2020-07-10,NA,Interventional,RUXCOVID,,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Recruiting,NA,Phase 3,402,Anticipated,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-06-08T08:32:06Z,2020-06-08T08:32:06Z
NCT04377750,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-05,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"May 8, 2021",Anticipated,2021-05-08,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,NA,Phase 4,500,Anticipated,Hadassah Medical Organization,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No plan,2020-06-01T09:24:30Z,2020-06-01T09:24:30Z
NCT04368793,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,,Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,Recruiting,NA,N/A,300,Anticipated,China-Japan Friendship Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:37Z,2020-06-01T09:25:37Z
NCT04368377,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:41Z,2020-06-01T09:25:41Z
NCT04366947,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting,"Active, not recruiting",NA,N/A,60,Anticipated,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,the investigators will decide after study finishing,2020-06-01T09:25:51Z,2020-06-01T09:25:51Z
NCT04366297,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"January 12, 2020",Actual,2020-01-12,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial,Completed,NA,N/A,41,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,the investigators will add data into manuscript,2020-06-01T09:25:55Z,2020-06-01T09:25:55Z
NCT04366271,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-07,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,MESCEL-COVID19,,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19,Recruiting,NA,Phase 2,106,Anticipated,"Hospital Infantil Universitario NiÃ±o JesÃºs, Madrid, Spain",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:25:56Z,2020-06-01T09:25:56Z
NCT04364022,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-04-24,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-24,2020-04-27,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,COPEP,,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial,Recruiting,NA,Phase 3,420,Anticipated,"University Hospital, Geneva",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:12Z,2020-06-01T09:26:12Z
NCT04363502,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-15,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:20Z,2020-06-01T09:26:20Z
NCT04363450,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-04-27,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"August 3, 2020",Anticipated,2020-08-03,"July 6, 2020",Anticipated,2020-07-06,NA,Interventional,HCQPreP,,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,NA,Phase 3,1700,Anticipated,Louisiana State University Health Sciences Center in New Orleans,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:20Z,2020-06-01T09:26:20Z
NCT04363437,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-06,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 26, 2020",Actual,2020-04-26,May 2020,2020-05-31,"June 14, 2020",Anticipated,2020-06-14,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COMBATCOVID19,,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study),Recruiting,NA,Phase 2,70,Anticipated,Maimonides Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:20Z,2020-06-01T09:26:20Z
NCT04363346,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-14,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia,Recruiting,NA,Phase 1,12,Anticipated,"Masonic Cancer Center, University of Minnesota",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:21Z,2020-06-01T09:26:21Z
NCT04363203,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-07,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,August 2021,Anticipated,2021-08-31,March 2021,Anticipated,2021-03-31,NA,Interventional,VA-REACH,,VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),"Active, not recruiting",NA,Phase 3,300,Anticipated,San Francisco VA Health Care System,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:22Z,2020-06-01T09:26:22Z
NCT04361253,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-23,NA,NA,2020-05-14,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,(ESCAPE),,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,"A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity",Recruiting,NA,Phase 3,220,Anticipated,Brigham and Women's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,Beginning 3 months after study publication. No end date.,Proposals should be submitted to rmkaufman@bwh.harvard.edu.,NA,Yes,Deidentified data will be made available upon request to the principal investigator following the publication of the primary manuscript.,2020-06-01T09:26:36Z,2020-06-01T09:26:36Z
NCT04393961,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"August 29, 2020",Anticipated,2020-08-29,"July 29, 2020",Anticipated,2020-07-29,NA,Interventional,NA,,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,NA,N/A,600,Anticipated,ProofPilot,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,,As soon reasonably sized data sets are available.,No personally identifiable information will be provided. Those who wish to access must have a ProofPilot account. All access must be approved by study investigators.,http://go.proofpilot.com,Yes,"Given the enormous policy and health implications, we will be making results available as soon as there are sufficient data sets to analyze. We will also provide our study design for replication in other environments and via other tests.",2020-06-01T09:22:34Z,2020-06-01T09:22:34Z
NCT04385095,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-Î²1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection,Recruiting,NA,Phase 2,400,Anticipated,Synairgen Research Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share data,2020-06-01T09:23:36Z,2020-06-01T09:23:36Z
NCT04368988,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-26,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"July 31, 2021",Anticipated,2021-07-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects",Recruiting,NA,Phase 1,131,Anticipated,Novavax,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:35Z,2020-06-01T09:25:35Z
NCT04368923,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-04-28,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"March 15, 2020",Actual,2020-03-15,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 15, 2020",Anticipated,2020-05-15,NA,Interventional,NA,,Management of Covid-19 Patients During Home Isolation,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",NA,N/A,60,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:35Z,2020-06-01T09:25:35Z
NCT04368260,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,NA,N/A,40,Anticipated,University of Virginia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,Starting 6 months after publication,Requests to made to Principal Investigator,NA,Yes,All individual participant data (IPD) that underlie results in a publication will be shared.,2020-06-01T09:25:41Z,2020-06-01T09:25:41Z
NCT04368000,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-18,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 29, 2020",Actual,2020-04-29,April 2020,2020-04-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,PAPR,,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,N/A,60,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:43Z,2020-06-01T09:25:43Z
NCT04366960,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-14,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,X-Covid 19,,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial,Recruiting,NA,Phase 3,2712,Anticipated,Niguarda Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:25:51Z,2020-06-01T09:25:51Z
NCT04366791,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-21,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,RESCUE 1-19,,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,The RESCUE 1-19 Trial: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,Recruiting,NA,Phase 1/Phase 2,10,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,"No
Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.",2020-06-01T09:25:52Z,2020-06-01T09:25:52Z
NCT04365972,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-06,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial,Completed,NA,N/A,20,Actual,Tel Aviv University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:59Z,2020-06-01T09:25:59Z
NCT04365608,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-04-27,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope,Recruiting,NA,N/A,90,Anticipated,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after manuscript publishing,NA,NA,Yes,NA,2020-06-01T09:26:01Z,2020-06-01T09:26:01Z
NCT04365309,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"February 10, 2020",Actual,2020-02-10,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,April 2020,Anticipated,2020-04-30,NA,Interventional,PEAC,,Protective Effect of Aspirin on COVID-19 Patients,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,NA,Phase 2/Phase 3,128,Anticipated,Xijing Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:03Z,2020-06-01T09:26:03Z
NCT04365257,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-13,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,PREVENT,,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection,Recruiting,NA,Phase 2,220,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:03Z,2020-06-01T09:26:03Z
NCT04365153,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-20,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19,Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury and Hyperinflammation,Recruiting,NA,Phase 2,45,Anticipated,The Cleveland Clinic,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:04Z,2020-06-01T09:26:04Z
NCT04365127,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-04-24,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-24,2020-04-28,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"April 17, 2021",Anticipated,2021-04-17,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men",Recruiting,NA,Phase 1,40,Anticipated,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:04Z,2020-06-01T09:26:04Z
NCT04363593,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-24,NA,NA,2020-05-04,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"November 4, 2020",Anticipated,2020-11-04,"November 4, 2020",Anticipated,2020-11-04,NA,Interventional,ROCOCO,,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Recruiting,NA,N/A,3200,Anticipated,Centre Hospitalier de Cornouaille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:26:19Z,2020-06-01T09:26:19Z
NCT04367168,"ClinicalTrials.gov processed this data on June 01, 2020",2020-04-24,NA,NA,2020-05-26,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 27, 2020",Actual,2020-05-27,April 2020,2020-04-30,"April 27, 2021",Anticipated,2021-04-27,"April 27, 2021",Anticipated,2021-04-27,NA,Interventional,ColchiVID,,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,"Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection",Recruiting,NA,Phase 2,174,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,6 months after publication of the clinical trial,Reviewers of scientific journals and researchers who contact the principal researcher by e-mail,NA,Yes,All IPD that underlie results in a publication,2020-06-02T08:28:59Z,2020-06-02T08:28:59Z
NCT04363827,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-24,NA,NA,2020-05-29,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,PROTECT,,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,2300,Anticipated,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:42:22Z,2020-06-07T08:42:22Z
NCT04372589,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-24,NA,NA,2020-06-01,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 20, 2020",Actual,2020-05-20,April 2020,2020-04-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),Antithrombotic Therapy to Ameliorate Complications of COVID-19,Recruiting,NA,Phase 2/Phase 3,3000,Anticipated,University of Manitoba,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:31:51Z,2020-06-08T08:31:51Z
NCT04363606,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-24,NA,NA,2020-06-03,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"May 27, 2020",Actual,2020-05-27,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,April 2021,Anticipated,2021-04-30,NA,Interventional,FatCovid-19,,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Chronic Fatigue Etiology and Recovery in Covid-19 Patients in Intensive Care Unit : the Role of Fatigability,Recruiting,NA,N/A,52,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:32:03Z,2020-06-08T08:32:03Z
NCT04362813,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-24,NA,NA,2020-06-02,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 30, 2020",Actual,2020-04-30,June 2020,2020-06-30,"October 16, 2020",Anticipated,2020-10-16,"July 10, 2020",Anticipated,2020-07-10,NA,Interventional,CAN-COVID,,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Recruiting,NA,Phase 3,450,Anticipated,Novartis,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2020-06-08T08:32:04Z,2020-06-08T08:32:04Z
NCT04392778,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-25,NA,NA,2020-05-17,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Recruiting,NA,Phase 1/Phase 2,30,Anticipated,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:41Z,2020-06-01T09:22:41Z
NCT04372017,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-25,NA,NA,2020-05-14,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 14, 2020",Anticipated,2020-05-14,May 2020,2020-05-31,"April 20, 2023",Anticipated,2023-04-20,"April 20, 2022",Anticipated,2022-04-20,NA,Interventional,NA,,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection",Recruiting,NA,Phase 3,1739,Anticipated,Sanford Health,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:09Z,2020-06-01T09:25:09Z
NCT04369742,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-25,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Treating COVID-19 With Hydroxychloroquine (TEACH),"Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults",Recruiting,NA,Phase 2,626,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests should be directed to mark.mulligan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-06-01T09:25:30Z,2020-06-01T09:25:30Z
NCT04365699,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-25,NA,NA,2020-04-25,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-25,2020-04-28,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Recruiting,NA,Phase 2,500,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-06-01T09:26:00Z,2020-06-01T09:26:00Z
NCT04364802,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-25,NA,NA,2020-05-12,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,PIIPPI,,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic,Recruiting,NA,Phase 2,250,Anticipated,University of Kentucky,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:26:06Z,2020-06-01T09:26:06Z
NCT04373824,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-26,NA,NA,2020-05-01,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-04,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"July 25, 2020",Anticipated,2020-07-25,"July 25, 2020",Anticipated,2020-07-25,NA,Interventional,NA,,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,NA,N/A,50,Anticipated,Max Healthcare Insititute Limited,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:56Z,2020-06-01T09:24:56Z
NCT04370782,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-26,NA,NA,2020-05-14,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Recruiting,NA,Phase 4,750,Anticipated,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:21Z,2020-06-01T09:25:21Z
NCT04365985,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-26,NA,NA,2020-05-07,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,May 2020,Anticipated,2020-05-31,NA,Interventional,SINK COVID-19,,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,NA,Phase 2,500,Anticipated,William Beaumont Hospitals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:57Z,2020-06-01T09:25:57Z
NCT04365738,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-26,NA,NA,2020-04-26,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 26, 2020",Actual,2020-04-26,"April 10, 2020",Actual,2020-04-10,NA,Interventional,NA,,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,N/A,270,Actual,Istanbul Bilgi University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:26:00Z,2020-06-01T09:26:00Z
NCT04389710,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"April 14, 2021",Anticipated,2021-04-14,"April 14, 2021",Anticipated,2021-04-14,NA,Interventional,NA,,Convalescent Plasma for the Treatment of COVID-19,Convalescent Plasma for the Treatment of Patients With COVID-19,Recruiting,NA,Phase 2,100,Anticipated,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:04Z,2020-06-01T09:23:04Z
NCT04379453,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-07,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"April 27, 2020",Anticipated,2020-04-27,"April 27, 2020",Anticipated,2020-04-27,NA,Interventional,NA,,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,NA,N/A,10,Anticipated,Hospital Israelita Albert Einstein,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:17Z,2020-06-01T09:24:17Z
NCT04374565,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-06,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"May 5, 2020",Anticipated,2020-05-05,May 2020,2020-05-31,"April 5, 2021",Anticipated,2021-04-05,"April 5, 2021",Anticipated,2021-04-05,NA,Interventional,NA,,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial,Recruiting,NA,Phase 2,29,Anticipated,University of Virginia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:24:51Z,2020-06-01T09:24:51Z
NCT04372693,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-01,2020-04-29,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,(COVID-19),,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement,Enrolling by invitation,NA,N/A,180,Anticipated,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:25:05Z,2020-06-01T09:25:05Z
NCT04370262,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-12,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 7, 2021",Anticipated,2021-04-07,"September 7, 2020",Anticipated,2020-09-07,NA,Interventional,MATCH,,Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19,"A Multi-site, Randomized, Double-Blind, Multi-Arm Historical Control, Comparative Trial of the Safety and Efficacy of Hydroxychloroquine, and the Combination of HCQ and Famotidine for the Treatment of COVID-19",Recruiting,NA,Phase 3,1170,Anticipated,Northwell Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:25Z,2020-06-01T09:25:25Z
NCT04369456,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-04-30,2020-04-27,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"October 22, 2020",Anticipated,2020-10-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovidT,,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,NA,N/A,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:32Z,2020-06-01T09:25:32Z
NCT04369365,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"December 27, 2020",Anticipated,2020-12-27,"August 27, 2020",Anticipated,2020-08-27,NA,Interventional,NA,,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,NA,Phase 2,200,Anticipated,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:32Z,2020-06-01T09:25:32Z
NCT04369066,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"January 28, 2021",Anticipated,2021-01-28,"October 28, 2020",Anticipated,2020-10-28,NA,Interventional,Curie-O-SA,,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie","COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie",Recruiting,NA,N/A,2500,Anticipated,Institut Curie,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:34Z,2020-06-01T09:25:34Z
NCT04367831,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-17,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"May 2, 2020",Actual,2020-05-02,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,November 2020,Anticipated,2020-11-30,NA,Interventional,IMPROVE,,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID),Recruiting,NA,Phase 4,100,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:44Z,2020-06-01T09:25:44Z
NCT04367545,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-04-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,MolCOVID,,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Recruiting,NA,N/A,50,Anticipated,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:46Z,2020-06-01T09:25:46Z
NCT04367077,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-05-13,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,August 2022,Anticipated,2022-08-31,September 2021,Anticipated,2021-09-30,NA,Interventional,MACoVIA,,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStemÂ® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2/Phase 3,400,Anticipated,"Athersys, Inc",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:50Z,2020-06-01T09:25:50Z
NCT04366180,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-27,NA,NA,2020-04-28,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19,Recruiting,NA,N/A,314,Anticipated,Biosearch S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:56Z,2020-06-01T09:25:56Z
NCT04368728,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-27,NA,NA,2020-06-04,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"April 29, 2020",Actual,2020-04-29,June 2020,2020-06-30,"January 23, 2023",Anticipated,2023-01-23,"June 28, 2021",Anticipated,2021-06-28,NA,Interventional,NA,,"Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS",Recruiting,NA,Phase 1,7600,Anticipated,Biontech SE,,21,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2020-06-08T08:31:59Z,2020-06-08T08:31:59Z
NCT04379154,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-28,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"November 16, 2020",Anticipated,2020-11-16,"June 28, 2020",Anticipated,2020-06-28,NA,Interventional,VOC-COVID,,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19),Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2: Predictive Interest in Short-term Evolution,Recruiting,NA,N/A,60,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:20Z,2020-06-01T09:24:20Z
NCT04376476,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-28,NA,NA,2020-05-07,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"June 5, 2021",Anticipated,2021-06-05,"June 5, 2021",Anticipated,2021-06-05,NA,Interventional,HPI-COVID-19,,Host-pathogen Interactions During SARS-CoV-2 Infection,Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19),Recruiting,NA,N/A,450,Anticipated,Hospices Civils de Lyon,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:37Z,2020-06-01T09:24:37Z
NCT04371640,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-28,NA,NA,2020-05-05,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,SirCO-1,,Sirolimus in COVID-19 Phase 1,"A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)",Recruiting,NA,Phase 1,40,Anticipated,Thomas Jefferson University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:12Z,2020-06-01T09:25:12Z
NCT04371510,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-28,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"February 22, 2021",Anticipated,2021-02-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovid-D,,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,NA,N/A,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:25:13Z,2020-06-01T09:25:13Z
NCT04371419,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-28,NA,NA,2020-05-14,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Recruiting,NA,N/A,15000,Anticipated,"National Bureau of Economic Research, Inc.",,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:15Z,2020-06-01T09:25:15Z
NCT04371029,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-28,NA,NA,2020-05-11,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,June 2020,Anticipated,2020-06-30,NA,Interventional,COVISLEEP,,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,NA,N/A,25,Anticipated,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:19Z,2020-06-01T09:25:19Z
NCT04406181,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-28,NA,NA,2020-05-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,"January 1, 2021",Anticipated,2021-01-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Effect on the COVID-19 Pandemic-induced Reduction in Elective Surgery on Medical Events and Psychological Well-being of Patients Waiting for Cardiac Surgery,Recruiting,NA,N/A,200,Anticipated,Universitair Ziekenhuis Brussel,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-06T08:47:49Z,2020-06-06T08:47:49Z
NCT04371393,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-28,NA,NA,2020-05-28,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,MSCs in COVID-19 ARDS,Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 3,300,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.",Anyone who wishes to access the data.,NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2020-06-06T08:49:16Z,2020-06-06T08:49:16Z
NCT04370886,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-28,NA,NA,2020-05-28,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"May 10, 2020",Actual,2020-05-10,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19,Completed,NA,N/A,456517,Actual,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-06T08:49:17Z,2020-06-06T08:49:17Z
NCT04385810,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 27, 2020",Actual,2020-04-27,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,DOCOV,,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Recruiting,NA,N/A,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:31Z,2020-06-01T09:23:31Z
NCT04384588,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-05-09,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-09,2020-05-12,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 6, 2021",Anticipated,2021-04-06,"April 6, 2021",Anticipated,2021-04-06,NA,Interventional,FALP-COVID,,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Fundacion Arturo Lopez Perez,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:40Z,2020-06-01T09:23:40Z
NCT04380532,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2020-06-01T09:24:08Z,2020-06-01T09:24:08Z
NCT04378712,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"January 21, 2020",Actual,2020-01-21,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"March 23, 2020",Actual,2020-03-23,NA,Interventional,NA,,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,N/A,90,Actual,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:24:23Z,2020-06-01T09:24:23Z
NCT04375202,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-05-03,2020-05-03,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-03,2020-05-05,Actual,"April 18, 2020",Actual,2020-04-18,May 2020,2020-05-31,"October 31, 2020",Anticipated,2020-10-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,COLVID-19,,Colchicine in COVID-19: a Pilot Study,Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study,Recruiting,NA,Phase 2,308,Anticipated,University Of Perugia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:46Z,2020-06-01T09:24:46Z
NCT04371367,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"October 27, 2020",Anticipated,2020-10-27,"June 27, 2020",Anticipated,2020-06-27,NA,Interventional,FORCE,,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia",Recruiting,NA,Phase 2,108,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:15Z,2020-06-01T09:25:15Z
NCT04370938,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-04-29,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 29, 2020",Actual,2020-04-29,April 2020,2020-04-30,"October 29, 2020",Anticipated,2020-10-29,"October 29, 2020",Anticipated,2020-10-29,NA,Interventional,NA,,Provider Burnout During COVID-19,Exploring Provider Burnout During the COVID-19 Pandemic,Recruiting,NA,N/A,250,Anticipated,University of Pittsburgh,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:25:20Z,2020-06-01T09:25:20Z
NCT04370288,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-04-30,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 19, 2020",Actual,2020-04-19,April 2020,2020-04-30,"September 21, 2020",Anticipated,2020-09-21,"September 20, 2020",Anticipated,2020-09-20,NA,Interventional,Covid-19,,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients,Recruiting,NA,Phase 1,20,Anticipated,Mashhad University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:25:25Z,2020-06-01T09:25:25Z
NCT04369820,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-29,NA,NA,2020-04-30,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,C5-COV,,C5a Receptor Expression - COVID-19 (C5-COV),C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19,Recruiting,NA,N/A,100,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:25:29Z,2020-06-01T09:25:29Z
NCT04372186,"ClinicalTrials.gov processed this data on June 02, 2020",2020-04-29,NA,NA,2020-05-27,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"October 5, 2020",Anticipated,2020-10-05,"August 5, 2020",Anticipated,2020-08-05,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia",Recruiting,NA,Phase 3,379,Anticipated,"Genentech, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform: https://vivli.org.
Further details on Roche's criteria for eligible studies are available here: https://vivli.org For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-06-03T08:31:02Z,2020-06-03T08:31:02Z
NCT04379531,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-30,NA,NA,2020-05-21,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-26,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,N/A,230,Actual,"Research and Practical Center of Medical Radiology, Department of Health Care of Moscow",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:17Z,2020-06-01T09:24:17Z
NCT04374942,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-30,NA,NA,2020-05-06,2020-04-30,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"January 30, 2022",Anticipated,2022-01-30,"August 27, 2020",Anticipated,2020-08-27,NA,Interventional,HEROs,,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,"Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada",Enrolling by invitation,NA,Phase 3,988,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"At the time of completion of the analysis of primary and secondary outcomes, the HEROS Steering Committee will review all applications for use of participant level data and make recommendations.",2020-06-01T09:24:48Z,2020-06-01T09:24:48Z
NCT04374032,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-30,NA,NA,2020-05-06,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 1, 2020",Actual,2020-05-01,April 2020,2020-04-30,"October 31, 2020",Anticipated,2020-10-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,120,Anticipated,Bosnalijek D.D,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:24:55Z,2020-06-01T09:24:55Z
NCT04373161,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-30,NA,NA,2020-05-05,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"April 22, 2020",Actual,2020-04-22,"April 22, 2020",Actual,2020-04-22,NA,Interventional,NA,,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,N/A,209,Actual,Swedish Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:01Z,2020-06-01T09:25:01Z
NCT04373135,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-30,NA,NA,2020-05-08,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,UC-COVID,,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19",A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.,Recruiting,NA,N/A,1000,Anticipated,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Within 4 months of study closure,Reasonable request to investigators,NA,Yes,Data requests for analysis may be approved by the investigators upon reasonable request.,2020-06-01T09:25:02Z,2020-06-01T09:25:02Z
NCT04372680,"ClinicalTrials.gov processed this data on May 29, 2020",2020-04-30,NA,NA,2020-04-30,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"September 22, 2020",Anticipated,2020-09-22,"September 22, 2020",Anticipated,2020-09-22,NA,Interventional,INVICTUS,,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,"WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial",Recruiting,NA,N/A,200,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:25:05Z,2020-06-01T09:25:05Z
NCT04408066,"ClinicalTrials.gov processed this data on June 05, 2020",2020-04-30,NA,NA,2020-06-02,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 30, 2020",Actual,2020-04-30,June 2020,2020-06-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,CAPTURE,,COVID-19: A POC Test Under Research & Evaluation,Specimen Collection for Development and Performance Evaluation of the LumiraDx Platform Point of Care Tests for Sars-Cov-2 IgG/IgM & Antigen to be Used as an Aid in Diagnosis of COVID-19,Recruiting,NA,N/A,2000,Anticipated,LumiraDx UK Limited,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:30:52Z,2020-06-08T08:30:52Z
NCT04378738,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-01,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 8, 2020",Anticipated,2020-05-08,"May 7, 2020",Anticipated,2020-05-07,NA,Interventional,NA,,Social Media and Covid19 Pandemic,The Role of Social Media as an Information Source in Covid19 Pandemic,Enrolling by invitation,NA,N/A,212,Anticipated,Acibadem University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,if requested to.,2020-06-01T09:24:23Z,2020-06-01T09:24:23Z
NCT04377789,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-01,NA,NA,2020-05-14,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Recruiting,NA,N/A,50,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:29Z,2020-06-01T09:24:29Z
NCT04375124,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-01,NA,NA,2020-05-14,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Treatment of Angiotensin Peptide (1-7) for COVID-19,Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19,Recruiting,NA,N/A,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:24:47Z,2020-06-01T09:24:47Z
NCT04374019,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-01,NA,NA,2020-05-05,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,"Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients",Recruiting,NA,Phase 2,240,Anticipated,University of Kentucky,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:55Z,2020-06-01T09:24:55Z
NCT04373707,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-01,NA,NA,2020-05-13,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"May 13, 2020",Actual,2020-05-13,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,COVI-DOSE,,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE,Recruiting,NA,Phase 4,602,Anticipated,"Central Hospital, Nancy, France",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:57Z,2020-06-01T09:24:57Z
NCT04374461,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-01,NA,NA,2020-05-28,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection,Recruiting,NA,Phase 2,86,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-06-06T08:49:10Z,2020-06-06T08:49:10Z
NCT04374786,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-01,NA,NA,2020-06-01,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"October 1, 2020",Anticipated,2020-10-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Effects of a Mobile App on Health and Well-being During COVID-19 Pandemic in House Staff at Banner University Medical Center Phoenix,Enrolling by invitation,NA,N/A,328,Anticipated,University of Arizona,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:31:50Z,2020-06-08T08:31:50Z
NCT04374591,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-02,NA,NA,2020-05-22,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series,Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series,"Active, not recruiting",NA,Early Phase 1,40,Anticipated,Mansoura University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:51Z,2020-06-01T09:24:51Z
NCT04374539,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-02,NA,NA,2020-05-02,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,"August 29, 2021",Anticipated,2021-08-29,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,REP-COVID,,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,NA,Phase 2,116,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:52Z,2020-06-01T09:24:52Z
NCT04374526,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-02,NA,NA,2020-05-27,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,LIFESAVER,,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.,Recruiting,NA,Phase 2/Phase 3,182,Anticipated,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-03T08:31:00Z,2020-06-03T08:31:00Z
NCT04392531,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-03,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection",Recruiting,NA,Phase 4,120,Anticipated,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:22:43Z,2020-06-01T09:22:43Z
NCT04376593,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-03,NA,NA,2020-05-04,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,PET/CT Imaging in COVID-19 Patients,18F-Î±vÎ²6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection,Enrolling by invitation,NA,Early Phase 1,10,Actual,"University of California, Davis",,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:37Z,2020-06-01T09:24:37Z
NCT04375098,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-03,NA,NA,2020-05-04,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"May 4, 2020",Anticipated,2020-05-04,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Recruiting,NA,Phase 2,30,Anticipated,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:47Z,2020-06-01T09:24:47Z
NCT04376814,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-03,NA,NA,2020-05-28,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"March 29, 2020",Actual,2020-03-29,May 2020,2020-05-31,"May 25, 2020",Anticipated,2020-05-25,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Enrolling by invitation,NA,N/A,40,Actual,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-03T08:30:58Z,2020-06-03T08:30:58Z
NCT04391712,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-04,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Recruiting,NA,Phase 2,20,Anticipated,Lowell General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:22:49Z,2020-06-01T09:22:49Z
NCT04385043,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-04,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 15, 2021",Anticipated,2021-05-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,COV2-CP,,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection,Recruiting,NA,Phase 2/Phase 3,400,Anticipated,University of Catanzaro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:37Z,2020-06-01T09:23:37Z
NCT04379336,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-04,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"April 28, 2021",Anticipated,2021-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial",Recruiting,NA,Phase 3,500,Anticipated,TASK Applied Science,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2020-06-01T09:24:18Z,2020-06-01T09:24:18Z
NCT04377477,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-04,NA,NA,2020-05-06,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"May 10, 2020",Anticipated,2020-05-10,May 2020,2020-05-31,"July 23, 2022",Anticipated,2022-07-23,"May 10, 2021",Anticipated,2021-05-10,NA,Interventional,COLOR-19,,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19),Recruiting,NA,N/A,30,Anticipated,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available starting six months from the publication and for five years.,"Written request to principal investigator , indicating the details of the data requested, the reasons of the inquiry and the purpose of the data use; data will be released after Local Ethics Committee approval. Data will be released only for no-profit use, in particular for research purposes.",NA,Yes,All Individual Participant Data that underlie results in the publication,2020-06-01T09:24:31Z,2020-06-01T09:24:31Z
NCT04378803,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-04,NA,NA,2020-05-27,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Mindfulness Training for Seniors,Mindfulness Training for Older Adults During the COVID-19 Pandemic,"Active, not recruiting",NA,N/A,53,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-02T08:28:47Z,2020-06-02T08:28:47Z
NCT04388527,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-04,NA,NA,2020-05-27,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2",Recruiting,NA,Phase 1,50,Anticipated,University of Pennsylvania,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-03T08:30:44Z,2020-06-03T08:30:44Z
NCT04377659,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-04,NA,NA,2020-05-27,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection,Recruiting,NA,Phase 2,40,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-06-03T08:30:57Z,2020-06-03T08:30:57Z
NCT04380818,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-04,NA,NA,2020-05-28,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"July 1, 2021",Anticipated,2021-07-01,"May 4, 2021",Anticipated,2021-05-04,NA,Interventional,NA,,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study,Recruiting,NA,N/A,106,Anticipated,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Protocol/ICF from approval Individual epidemiological and clinical data after recruitment is complete.,NA,NA,Yes,Individual epidemiological and clinical data will be shared after recruitment is complete.,2020-06-06T08:48:59Z,2020-06-06T08:48:59Z
NCT04377672,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-04,NA,NA,2020-05-31,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-31,2020-06-02,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,"May 28, 2022",Anticipated,2022-05-28,"May 28, 2021",Anticipated,2021-05-28,NA,Interventional,NA,,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2,Recruiting,NA,Phase 1,30,Anticipated,Johns Hopkins University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:42:03Z,2020-06-07T08:42:03Z
NCT04377620,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-04,NA,NA,2020-06-03,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"May 24, 2020",Actual,2020-05-24,June 2020,2020-06-30,"July 29, 2020",Anticipated,2020-07-29,"July 29, 2020",Anticipated,2020-07-29,NA,Interventional,NA,,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",Recruiting,NA,Phase 3,500,Anticipated,Incyte Corporation,,3,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:31:46Z,2020-06-08T08:31:46Z
NCT04376684,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-04,NA,NA,2020-06-02,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 28, 2020",Actual,2020-05-28,June 2020,2020-06-30,"December 21, 2020",Anticipated,2020-12-21,"December 21, 2020",Anticipated,2020-12-21,NA,Interventional,OSCAR,,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,"A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease",Recruiting,NA,Phase 2,800,Anticipated,GlaxoSmithKline,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2020-06-08T08:31:48Z,2020-06-08T08:31:48Z
NCT04375397,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-04,NA,NA,2020-06-03,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,"September 10, 2020",Anticipated,2020-09-10,"August 13, 2020",Anticipated,2020-08-13,NA,Interventional,iNSPIRE,,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Recruiting,NA,Phase 2,46,Anticipated,AbbVie,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-06-08T08:31:49Z,2020-06-08T08:31:49Z
NCT04392713,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-17,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy of Ivermectin in COVID-19,Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial,Recruiting,NA,N/A,100,Anticipated,"Combined Military Hospital, Pakistan",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:42Z,2020-06-01T09:22:42Z
NCT04389372,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-14,2020-05-11,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"March 15, 2020",Actual,2020-03-15,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,March 2021,Anticipated,2021-03-31,NA,Interventional,ChroMig-Smart,,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency,Recruiting,NA,N/A,50,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:06Z,2020-06-01T09:23:06Z
NCT04383613,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-19,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"December 11, 2020",Anticipated,2020-12-11,"December 11, 2020",Anticipated,2020-12-11,NA,Interventional,COVID-PRONE,,Prone Positioning for Patients on General Medical Wards With COVID19,Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE],Recruiting,NA,N/A,350,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:47Z,2020-06-01T09:23:47Z
NCT04381884,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-23,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-23,2020-05-27,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Recruiting,NA,Phase 2,45,Anticipated,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:58Z,2020-06-01T09:23:58Z
NCT04379661,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Recruiting,NA,N/A,52,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:15Z,2020-06-01T09:24:15Z
NCT04379492,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-08,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19,"Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection",Recruiting,NA,Phase 2,120,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-06-01T09:24:17Z,2020-06-01T09:24:17Z
NCT04379076,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"December 30, 2020",Anticipated,2020-12-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,ILIAD-7-UK,,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,publication,2020-06-01T09:24:21Z,2020-06-01T09:24:21Z
NCT04378920,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-05,NA,NA,2020-05-12,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"October 31, 2020",Anticipated,2020-10-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,LEAF-4L6715,,A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715),A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease,Recruiting,NA,Phase 1/Phase 2,180,Anticipated,Institut de Cancerologie Strasbourg Europe,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:22Z,2020-06-01T09:24:22Z
NCT04382768,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-06,NA,NA,2020-05-15,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,CÃ³rdobaTrail,,Inhaled Ibuprofen to Treat COVID-19,"Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.","Active, not recruiting",NA,N/A,40,Actual,QuÃ­mica Luar SRL,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:23:52Z,2020-06-01T09:23:52Z
NCT04382092,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-06,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 23, 2020",Actual,2020-03-23,May 2020,2020-05-31,"April 24, 2020",Actual,2020-04-24,"April 24, 2020",Actual,2020-04-24,NA,Interventional,NA,,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,N/A,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:57Z,2020-06-01T09:23:57Z
NCT04381858,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-06,NA,NA,2020-05-08,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Recruiting,NA,Phase 3,500,Anticipated,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:58Z,2020-06-01T09:23:58Z
NCT04380701,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-06,NA,NA,2020-05-11,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Biontech SE,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:07Z,2020-06-01T09:24:07Z
NCT04380519,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-06,NA,NA,2020-05-06,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"November 15, 2020",Anticipated,2020-11-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,NA,,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2/Phase 3,372,Anticipated,R-Pharm,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:08Z,2020-06-01T09:24:08Z
NCT04380376,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-06,NA,NA,2020-05-10,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,MICOV,,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,"Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19",Recruiting,NA,Phase 2,60,Anticipated,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:09Z,2020-06-01T09:24:09Z
NCT04385901,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-06,NA,NA,2020-06-03,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"May 19, 2020",Actual,2020-05-19,June 2020,2020-06-30,"April 19, 2022",Anticipated,2022-04-19,"April 19, 2022",Anticipated,2022-04-19,NA,Interventional,NA,,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Recruiting,NA,N/A,72,Anticipated,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:31:33Z,2020-06-08T08:31:33Z
NCT04390477,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Recruiting,NA,N/A,40,Anticipated,Bioithas SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:22:58Z,2020-06-01T09:22:58Z
NCT04390139,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,COVIDMES,,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,"A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19",Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Banc de Sang i Teixits,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:00Z,2020-06-01T09:23:00Z
NCT04390022,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-19,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 14, 2020",Anticipated,2020-05-14,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 4, 2020",Anticipated,2020-08-04,NA,Interventional,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Recruiting,NA,Phase 2,24,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:01Z,2020-06-01T09:23:01Z
NCT04384497,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-26,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"The investigators will be sharing the data, but the management plan is being designed.",2020-06-01T09:23:40Z,2020-06-01T09:23:40Z
NCT04381377,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-07,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of PolyoxidoniumÂ®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).",Recruiting,NA,Phase 2/Phase 3,394,Anticipated,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:02Z,2020-06-01T09:24:02Z
NCT04381000,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-08,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.,Recruiting,NA,N/A,170,Anticipated,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:24:04Z,2020-06-01T09:24:04Z
NCT04380961,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-12,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"September 16, 2020",Anticipated,2020-09-16,"June 25, 2020",Anticipated,2020-06-25,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Recruiting,NA,Phase 2,270,Anticipated,"Janssen Pharmaceutica N.V., Belgium",,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-06-01T09:24:04Z,2020-06-01T09:24:04Z
NCT04380909,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-07,NA,NA,2020-05-07,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,ROCO,,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Recruiting,NA,N/A,80,Anticipated,University of Bern,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:24:05Z,2020-06-01T09:24:05Z
NCT04382040,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-07,NA,NA,2020-06-03,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Recruiting,NA,Phase 2,50,Anticipated,MGC Pharmaceuticals d.o.o,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:31:41Z,2020-06-08T08:31:41Z
NCT04381936,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-07,NA,NA,2020-06-03,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"March 19, 2020",Actual,2020-03-19,June 2020,2020-06-30,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,RECOVERY,,Randomised Evaluation of COVID-19 Therapy,Randomised Evaluation of COVID-19 Therapy,Recruiting,NA,Phase 2/Phase 3,12000,Anticipated,University of Oxford,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,Proposals for substudies must be approved by the Trial Steering Committee. Procedures for accessing the data for this study are available on https://www.ndph.ox.ac.uk/data-access,https://www.ndph.ox.ac.uk/data-access,Yes,The data-sharing plans for this study will be made available at a later date.,2020-06-08T08:31:42Z,2020-06-08T08:31:42Z
NCT04382066,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-07,NA,NA,2020-06-02,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,APLICOV-PC,,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Recruiting,NA,Phase 1,27,Anticipated,PharmaMar,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2020-06-08T08:31:40Z,2020-06-08T08:31:40Z
NCT04390464,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-08,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 7, 2021",Anticipated,2021-05-07,NA,Interventional,TACTIC-R,,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,NA,Phase 4,1167,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:22:58Z,2020-06-01T09:22:58Z
NCT04389294,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-08,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Recruiting,NA,N/A,300,Anticipated,"Hospital for Special Surgery, New York",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:06Z,2020-06-01T09:23:06Z
NCT04386694,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-08,NA,NA,2020-05-18,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Recruiting,NA,N/A,30,Anticipated,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:24Z,2020-06-01T09:23:24Z
NCT04382729,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-08,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial,Recruiting,NA,N/A,80,Anticipated,"University of Turin, Italy",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:23:52Z,2020-06-01T09:23:52Z
NCT04381988,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-08,NA,NA,2020-05-11,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID),Recruiting,NA,Phase 2,132,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-06-01T09:23:58Z,2020-06-01T09:23:58Z
NCT04382547,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-08,NA,NA,2020-05-26,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,NA,Phase 1/Phase 2,40,Anticipated,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-02T08:28:43Z,2020-06-02T08:28:43Z
NCT04384965,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-08,NA,NA,2020-05-28,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"November 1, 2022",Anticipated,2022-11-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,A Novel and Practical Accelerated Intermittent Theta Burst Protocol as a Substitute for Depressed Patients Needing Electroconvulsive Therapy During the COVID-19 Pandemic,Recruiting,NA,N/A,200,Anticipated,Centre for Addiction and Mental Health,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-03T08:30:49Z,2020-06-03T08:30:49Z
NCT04405986,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-08,NA,NA,2020-05-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 19, 2020",Actual,2020-05-19,May 2020,2020-05-31,"December 19, 2020",Anticipated,2020-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,BRAINCOV,,Exploring Brain Damages After COVID-19 Infection,Exploring Brain Damages After COVID-19 Infection,Recruiting,NA,N/A,38,Anticipated,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-06T08:47:50Z,2020-06-06T08:47:50Z
NCT04394416,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-08,NA,NA,2020-06-02,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 2, 2020",Actual,2020-06-02,June 2020,2020-06-30,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,NA,,Trial of Imatinib for Hospitalized Adults With COVID-19,Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19,Recruiting,NA,Phase 3,204,Anticipated,"University of Maryland, Baltimore",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:31:21Z,2020-06-08T08:31:21Z
NCT04382053,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-08,NA,NA,2020-06-03,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 27, 2020",Actual,2020-05-27,June 2020,2020-06-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function",Recruiting,NA,Phase 2,120,Anticipated,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2020-06-08T08:31:41Z,2020-06-08T08:31:41Z
NCT04389333,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-09,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"March 26, 2020",Actual,2020-03-26,May 2020,2020-05-31,"May 20, 2020",Anticipated,2020-05-20,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial",Recruiting,NA,N/A,40,Anticipated,Changhai Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:06Z,2020-06-01T09:23:06Z
NCT04385199,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-09,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Recruiting,NA,Phase 2,30,Anticipated,Henry Ford Health System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:23:35Z,2020-06-01T09:23:35Z
NCT04391140,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-10,NA,NA,2020-05-14,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS,Recruiting,NA,N/A,248,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:22:53Z,2020-06-01T09:22:53Z
NCT04385836,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-10,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"September 1, 2020",Anticipated,2020-09-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,NA,Early Phase 1,150,Anticipated,"Ministry of Health, Saudi Arabia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,NA,2020-06-01T09:23:30Z,2020-06-01T09:23:30Z
NCT04385017,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-10,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 11, 2020",Anticipated,2020-05-11,May 2020,2020-05-31,"June 12, 2021",Anticipated,2021-06-12,"June 12, 2021",Anticipated,2021-06-12,NA,Interventional,CoVInnate,,Role of Inflammasomes in COVID-19 Disease,Role of Inflammasomes in COVID-19 Disease,Recruiting,NA,N/A,40,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:23:37Z,2020-06-01T09:23:37Z
NCT04388514,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-11,NA,NA,2020-05-13,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"October 8, 2020",Anticipated,2020-10-08,"October 8, 2020",Anticipated,2020-10-08,NA,Interventional,CORMOR,,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,NA,N/A,90,Anticipated,Azienda Sanitaria-Universitaria Integrata di Udine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication,Contacting the Principal Investigator,NA,Yes,all IPD that underlie results in a publication,2020-06-01T09:23:11Z,2020-06-01T09:23:11Z
NCT04386850,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-11,NA,NA,2020-05-11,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"March 15, 2021",Anticipated,2021-03-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Oral 25-hydroxyvitamin D3 and COVID-19,Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The datasets used and analyzed during the current study will be available from the corresponding author on reasonable request.,2020-06-01T09:23:23Z,2020-06-01T09:23:23Z
NCT04386616,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-11,NA,NA,2020-05-19,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 22, 2020",Anticipated,2020-05-22,May 2020,2020-05-31,"October 27, 2020",Anticipated,2020-10-27,"September 24, 2020",Anticipated,2020-09-24,NA,Interventional,COVASTIL,,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2,300,Anticipated,"Genentech, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-06-01T09:23:26Z,2020-06-01T09:23:26Z
NCT04384900,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-11,NA,NA,2020-05-12,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"May 11, 2020",Actual,2020-05-11,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,PROVENT-COVID,,Accelerated Prone Position Ventilation of Patients With COVID-19,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,NA,N/A,150,Anticipated,Nordsjaellands Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,9 months after publication of primary results,NA,NA,Yes,De-identified data will be made publicly available 9 months after the publication of the outcome data according to the recent ICMJE recommendations,2020-06-01T09:23:38Z,2020-06-01T09:23:38Z
NCT04386291,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-11,NA,NA,2020-05-27,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,"January 30, 2022",Anticipated,2022-01-30,"May 19, 2021",Anticipated,2021-05-19,NA,Interventional,NA,,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Meditation and Yoga for Heightened Anxiety Related to COVID-19,Recruiting,NA,N/A,360,Anticipated,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-02T08:28:37Z,2020-06-02T08:28:37Z
NCT04391127,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-12,NA,NA,2020-05-25,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Recruiting,NA,Phase 3,200,Anticipated,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:53Z,2020-06-01T09:22:53Z
NCT04390191,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-12,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Interventional,PAP-COVID,,Early CPAP in COVID-19 Confirmed or Suspected Patients,Early Continuous Positive Airway Pressure (CPAP) in COVID-19 Confirmed or Suspected Patients,Recruiting,NA,N/A,200,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:59Z,2020-06-01T09:22:59Z
NCT04389944,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-12,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"March 31, 2020",Actual,2020-03-31,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Recruiting,NA,N/A,15,Anticipated,"University Hospital, Basel, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:01Z,2020-06-01T09:23:01Z
NCT04389385,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-12,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia,"Active, not recruiting",NA,Phase 1,60,Anticipated,TC Erciyes University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:23:06Z,2020-06-01T09:23:06Z
NCT04387292,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-12,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,June 2020,Anticipated,2020-06-30,May 2020,2020-05-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,SOCOVID,,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,NA,N/A,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:23:21Z,2020-06-01T09:23:21Z
NCT04412330,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-12,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,OPTIMAL,,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study,Recruiting,NA,N/A,40,Anticipated,University of Kentucky,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-07T08:39:33Z,2020-06-07T08:39:33Z
NCT04390412,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-13,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Low Dose Radiotherapy in COVID-19 Pneumonia,Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial,Recruiting,NA,Phase 1/Phase 2,5,Anticipated,Shahid Beheshti University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After the completion of trial for one year.,Verified researchers,NA,Yes,IPD will be shared after the completion of study to other researchers.,2020-06-01T09:22:58Z,2020-06-01T09:22:58Z
NCT04388683,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-13,NA,NA,2020-05-14,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"July 31, 2021",Anticipated,2021-07-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NO-COVID-19,,Inhaled Nitric Oxide for Preventing Progression in COVID-19,Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.,Recruiting,NA,Phase 2,42,Anticipated,Tufts Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data from this pilot study will be used to plan future a larger randomized controlled outcome trial.,2020-06-01T09:23:10Z,2020-06-01T09:23:10Z
NCT04405076,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-13,NA,NA,2020-05-26,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,August 2021,Anticipated,2021-08-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older",Recruiting,NA,Phase 2,600,Anticipated,"ModernaTX, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-02T08:27:39Z,2020-06-02T08:27:39Z
NCT04388826,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-13,NA,NA,2020-05-27,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 27, 2020",Anticipated,2020-05-27,May 2020,2020-05-31,"August 30, 2020",Anticipated,2020-08-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2,40,Anticipated,Veru Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-02T08:28:34Z,2020-06-02T08:28:34Z
NCT04392414,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-13,NA,NA,2020-06-02,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 15, 2020",Anticipated,2020-09-15,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Recruiting,NA,Phase 2,60,Anticipated,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2020-06-08T08:31:23Z,2020-06-08T08:31:23Z
NCT04389840,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-13,NA,NA,2020-06-03,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"June 3, 2020",Actual,2020-06-03,May 2020,2020-05-31,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,NA,Phase 2/Phase 3,524,Anticipated,Chimerix,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:31:27Z,2020-06-08T08:31:27Z
NCT04390503,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-14,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma for COVID-19 Close Contacts,"A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases",Recruiting,NA,Phase 2,200,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:58Z,2020-06-01T09:22:58Z
NCT04390516,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-14,NA,NA,2020-06-02,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"March 24, 2020",Actual,2020-03-24,June 2020,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,"May 4, 2020",Actual,2020-05-04,NA,Interventional,NA,,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,"Active, not recruiting",NA,N/A,197,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:31:26Z,2020-06-08T08:31:26Z
NCT04395144,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-15,NA,NA,2020-05-18,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,COVAYDE,,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Recruiting,NA,N/A,346,Anticipated,HÃ´pital de Verdun,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:22:25Z,2020-06-01T09:22:25Z
NCT04394182,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-15,NA,NA,2020-05-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"April 21, 2020",Actual,2020-04-21,May 2020,2020-05-31,"April 21, 2021",Anticipated,2021-04-21,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,ULTRA-COVID,,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers,Recruiting,NA,N/A,15,Anticipated,Fundacion GenesisCare,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Medical history and biographical and clinical data of each patient will be recorded and shared.
The overall results of any research conducted will be available on study data publication.",2020-06-01T09:22:32Z,2020-06-01T09:22:32Z
NCT04392323,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-15,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"July 31, 2020",Anticipated,2020-07-31,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,NA,N/A,500,Anticipated,Northwell Health,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:45Z,2020-06-01T09:22:45Z
NCT04392232,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-15,NA,NA,2020-05-18,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,NA,Phase 2,100,Anticipated,TriHealth Inc.,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:45Z,2020-06-01T09:22:45Z
NCT04392141,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-15,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"October 1, 2020",Anticipated,2020-10-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:46Z,2020-06-01T09:22:46Z
NCT04391179,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-15,NA,NA,2020-05-31,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-31,2020-06-02,Actual,"May 31, 2020",Actual,2020-05-31,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,DICER,,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Recruiting,NA,Phase 2,80,Anticipated,University of Michigan,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:41:36Z,2020-06-07T08:41:36Z
NCT04395105,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-16,NA,NA,2020-05-21,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Dexamethasone Versus Usual Care for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial,Recruiting,NA,Phase 3,284,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:26Z,2020-06-01T09:22:26Z
NCT04393727,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-16,NA,NA,2020-05-19,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,TSUNAMI,,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial,Recruiting,NA,Phase 2,126,Anticipated,"Azienda Ospedaliero, Universitaria Pisana",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:35Z,2020-06-01T09:22:35Z
NCT04407208,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-16,NA,NA,2020-05-30,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Recruiting,NA,Phase 1,10,Anticipated,Biofarma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-07T08:40:57Z,2020-06-07T08:40:57Z
NCT04398004,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-17,NA,NA,2020-05-21,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-26,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"May 6, 2022",Anticipated,2022-05-06,"May 6, 2022",Anticipated,2022-05-06,NA,Interventional,ACHIEVE,,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Recruiting,NA,Phase 2,90,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:04Z,2020-06-01T09:22:04Z
NCT04394442,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-17,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"March 21, 2020",Actual,2020-03-21,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Hydroxychloroquine in COVID-19 Patients,Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:22:30Z,2020-06-01T09:22:30Z
NCT04403269,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-18,NA,NA,2020-05-22,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"May 5, 2021",Anticipated,2021-05-05,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,GERONIMO 19,,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE","""STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE"" GERONIMO 19",Recruiting,NA,Phase 2,35,Anticipated,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:21:26Z,2020-06-01T09:21:26Z
NCT04402918,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-18,NA,NA,2020-05-25,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"May 17, 2020",Actual,2020-05-17,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"May 19, 2020",Anticipated,2020-05-19,NA,Interventional,TRANSCOVID,,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy,Recruiting,NA,N/A,160,Anticipated,Centre Hospitalier Universitaire de Besancon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:21:29Z,2020-06-01T09:21:29Z
NCT04393792,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-18,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?,Recruiting,NA,Phase 1,40,Anticipated,Hampshire Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:35Z,2020-06-01T09:22:35Z
NCT04393038,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-18,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,Mir-Age,,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,"A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged â‰¥ 65 and Patients Aged â‰¥18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.",Recruiting,NA,Phase 2/Phase 3,1034,Anticipated,Abivax S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:39Z,2020-06-01T09:22:39Z
NCT04405999,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-18,NA,NA,2020-05-26,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,NA,,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Recruiting,NA,Phase 4,140,Anticipated,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-02T08:27:04Z,2020-06-02T08:27:04Z
NCT04395807,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-18,NA,NA,2020-06-04,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,May 2021,Anticipated,2021-05-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVID HELMET,,Helmet CPAP Versus HFNC in COVID-19,Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial,Recruiting,NA,N/A,120,Anticipated,Lund University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:31:19Z,2020-06-08T08:31:19Z
NCT04402203,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-19,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,NA,Phase 2/Phase 3,50,Anticipated,Bangladesh Medical Research Council (BMRC),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:21:33Z,2020-06-01T09:21:33Z
NCT04399746,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-19,NA,NA,2020-05-20,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"March 15, 2020",Actual,2020-03-15,May 2020,2020-05-31,"June 10, 2020",Anticipated,2020-06-10,"May 20, 2020",Actual,2020-05-20,NA,Interventional,IvAzCol,,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol,Recruiting,NA,N/A,30,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:21:51Z,2020-06-01T09:21:51Z
NCT04399005,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-19,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,"June 10, 2020",Anticipated,2020-06-10,"June 5, 2020",Anticipated,2020-06-05,NA,Interventional,NA,,The Efficacy Comparing Daily and After-each-case Room Disinfection.,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.,Recruiting,NA,N/A,240,Anticipated,The First Affiliated Hospital of Zhejiang Chinese Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,individual participant data sharing will be consider after study,2020-06-01T09:21:56Z,2020-06-01T09:21:56Z
NCT04407286,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-19,NA,NA,2020-05-27,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"May 19, 2020",Actual,2020-05-19,May 2020,2020-05-31,"May 18, 2021",Anticipated,2021-05-18,"August 18, 2020",Anticipated,2020-08-18,NA,Interventional,NA,,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Recruiting,NA,Phase 1,100,Anticipated,Arizona State University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2020-06-03T08:29:36Z,2020-06-03T08:29:36Z
NCT04397757,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-19,NA,NA,2020-05-29,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"November 13, 2020",Anticipated,2020-11-13,"September 13, 2020",Anticipated,2020-09-13,NA,Interventional,NA,,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.",Recruiting,NA,Phase 1,80,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:41:23Z,2020-06-07T08:41:23Z
NCT04397510,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-19,NA,NA,2020-06-01,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,NA,Phase 4,50,Anticipated,Frederick Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-07T08:41:24Z,2020-06-07T08:41:24Z
NCT04416360,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-19,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 5, 2020",Actual,2020-05-05,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CLIECO,,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak,Recruiting,NA,N/A,40,Anticipated,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:28:31Z,2020-06-08T08:28:31Z
NCT04397562,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-19,NA,NA,2020-06-02,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 29, 2020",Actual,2020-04-29,June 2020,2020-06-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,CORONA,,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Recruiting,NA,Phase 3,204,Anticipated,Biocad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:31:15Z,2020-06-08T08:31:15Z
NCT04403477,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-20,NA,NA,2020-05-24,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,NA,,Convalescent Plasma Therapy in Severe COVID-19 Infection,"Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT",Recruiting,NA,Phase 2,20,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2020-06-01T09:21:25Z,2020-06-01T09:21:25Z
NCT04401293,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-20,NA,NA,2020-05-21,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-26,Actual,"April 26, 2020",Actual,2020-04-26,May 2020,2020-05-31,"April 26, 2021",Anticipated,2021-04-26,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,NA,,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Recruiting,NA,Phase 3,308,Anticipated,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-01T09:21:40Z,2020-06-01T09:21:40Z
NCT04398277,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-20,NA,NA,2020-05-20,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,A Daily Coping Toolkit for Medical Personnel and First-Responders During the COVID-19 Pandemic,Recruiting,NA,N/A,1000,Anticipated,Kent State University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after data collection is complete,Contact the PI,NA,Yes,All data and materials will be made available.,2020-06-01T09:22:02Z,2020-06-01T09:22:02Z
NCT04397523,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-20,NA,NA,2020-05-20,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"April 29, 2021",Anticipated,2021-04-29,"April 29, 2021",Anticipated,2021-04-29,NA,Interventional,NA,,Efficacy and Safety of COVID-19 Convalescent Plasma,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety,Recruiting,NA,N/A,20,Anticipated,Institute for Transfusion Medicine of RNM,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:22:07Z,2020-06-01T09:22:07Z
NCT04397666,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-20,NA,NA,2020-05-20,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"November 15, 2020",Anticipated,2020-11-15,"September 15, 2020",Anticipated,2020-09-15,NA,Interventional,P20/09,,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19,Recruiting,NA,N/A,68,Anticipated,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:22:06Z,2020-06-01T09:22:06Z
NCT04402970,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-20,NA,NA,2020-06-02,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 30, 2020",Anticipated,2020-05-30,June 2020,2020-06-30,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,DORNASESARS2,,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Recruiting,NA,Phase 3,20,Anticipated,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-08T08:31:09Z,2020-06-08T08:31:09Z
NCT04401202,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-21,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Recruiting,NA,Phase 2,200,Anticipated,King Abdulaziz University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:21:41Z,2020-06-01T09:21:41Z
NCT04400305,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COVID-19,,"""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,NA,N/A,40,Anticipated,University of Victoria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:21:46Z,2020-06-01T09:21:46Z
NCT04399980,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,NA,Phase 2,60,Anticipated,The Cleveland Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:21:49Z,2020-06-01T09:21:49Z
NCT04399681,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 10, 2020",Actual,2020-05-10,May 2020,2020-05-31,"September 10, 2020",Anticipated,2020-09-10,"August 10, 2020",Anticipated,2020-08-10,NA,Interventional,NA,,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department,Recruiting,NA,N/A,100,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:21:51Z,2020-06-01T09:21:51Z
NCT04399109,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"May 19, 2021",Anticipated,2021-05-19,"May 19, 2021",Anticipated,2021-05-19,NA,Interventional,ReCOVER,,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),ReCOVER (Remote COVID-19 Evaluation and Response): a Prospective Non-randomised Controlled Trial to Evaluate the Effect of a Novel Smartphone Application-centric Model of Care for the Remote Monitoring of COVID-19 Patients in the Community.,Recruiting,NA,N/A,2000,Anticipated,"Prince of Wales Hospital, Sydney",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-01T09:21:55Z,2020-06-01T09:21:55Z
NCT04410549,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-21,NA,NA,2020-05-29,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"May 27, 2020",Anticipated,2020-05-27,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study,Recruiting,NA,N/A,10,Anticipated,IRCCS San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-06T08:46:25Z,2020-06-06T08:46:25Z
NCT04413006,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-21,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Self-compassion for Chronic Pain Virtual Group Treatment Program,A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery,Recruiting,NA,N/A,28,Anticipated,University of Manitoba,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:39:08Z,2020-06-07T08:39:08Z
NCT04412538,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:30:27Z,2020-06-08T08:30:27Z
NCT04402983,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-22,NA,NA,2020-05-22,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Recruiting,NA,N/A,34,Anticipated,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-01T09:21:29Z,2020-06-01T09:21:29Z
NCT04402840,"ClinicalTrials.gov processed this data on May 29, 2020",2020-05-22,NA,NA,2020-05-22,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,N/A,5,Anticipated,West Virginia University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-01T09:21:29Z,2020-06-01T09:21:29Z
NCT04411602,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-22,NA,NA,2020-05-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Patients With Severe Respiratory Distress Due to COVID-19,Recruiting,NA,Phase 1,90,Anticipated,Ascension South East Michigan,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:40:03Z,2020-06-07T08:40:03Z
NCT04407390,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-22,NA,NA,2020-05-29,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NR-COVID19,,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19",Recruiting,NA,Phase 2,100,Anticipated,University of Copenhagen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-07T08:40:53Z,2020-06-07T08:40:53Z
NCT04402879,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-22,NA,NA,2020-05-29,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,CORONA,,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic,Recruiting,NA,N/A,596,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:41:15Z,2020-06-07T08:41:15Z
NCT04408183,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-22,NA,NA,2020-06-02,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,"Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection in Healthcare Personnel",Recruiting,NA,Phase 2,225,Anticipated,"GeneOne Life Science, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:30:51Z,2020-06-08T08:30:51Z
NCT04401579,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-22,NA,NA,2020-06-04,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Estimate,"May 8, 2020",Actual,2020-05-08,"April 16, 2020",2020-04-16,"August 1, 2023",Anticipated,2023-08-01,"August 1, 2023",Anticipated,2023-08-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 2 (ACTT-II),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)",Recruiting,NA,Phase 3,1032,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-06-08T08:31:11Z,2020-06-08T08:31:11Z
NCT04406493,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-23,NA,NA,2020-05-27,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"April 28, 2021",Anticipated,2021-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Monitoring of Lung Fluid Status of Hospitalized COVID-19 Patients by Lung Impedance Technique,Recruiting,NA,N/A,50,Anticipated,Hillel Yaffe Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-02T08:26:47Z,2020-06-02T08:26:47Z
NCT04411433,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-23,NA,NA,2020-05-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"July 30, 2020",Anticipated,2020-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19",Recruiting,NA,Phase 3,1000,Anticipated,"Ministry of Health, Turkey",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:40:09Z,2020-06-07T08:40:09Z
NCT04406246,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-24,NA,NA,2020-05-27,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Recruiting,NA,Phase 4,150,Anticipated,Materno-Perinatal Hospital of the State of Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2020-06-02T08:26:56Z,2020-06-02T08:26:56Z
NCT04403685,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-24,NA,NA,2020-05-26,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"August 31, 2020",Anticipated,2020-08-31,"July 8, 2020",Anticipated,2020-07-08,NA,Interventional,TOCIBRAS,,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS),Recruiting,NA,Phase 3,150,Anticipated,BeneficÃªncia Portuguesa de SÃ£o Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-02T08:28:00Z,2020-06-02T08:28:00Z
NCT04408456,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-24,NA,NA,2020-05-29,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"March 1, 2020",Actual,2020-03-01,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,PEP-Q,,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Recruiting,NA,Phase 3,200,Anticipated,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2020-06-07T08:40:49Z,2020-06-07T08:40:49Z
NCT04412356,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-24,NA,NA,2020-06-03,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"February 1, 2021",Anticipated,2021-02-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,TTCOV19,,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Recruiting,NA,N/A,180,Anticipated,"Sahlgrenska University Hospital, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:30:28Z,2020-06-08T08:30:28Z
NCT04407182,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-25,NA,NA,2020-05-28,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"June 15, 2020",Anticipated,2020-06-15,"June 13, 2020",Anticipated,2020-06-13,NA,Interventional,NA,,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-06-03T08:29:40Z,2020-06-03T08:29:40Z
NCT04408209,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-25,NA,NA,2020-05-29,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"September 15, 2021",Anticipated,2021-09-15,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial,Recruiting,NA,N/A,60,Anticipated,National and Kapodistrian University of Athens,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-07T08:40:50Z,2020-06-07T08:40:50Z
NCT04417335,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-25,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 4,2014,Actual,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-08T08:28:00Z,2020-06-08T08:28:00Z
NCT04405310,"ClinicalTrials.gov processed this data on June 01, 2020",2020-05-26,NA,NA,2020-05-26,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"July 20, 2020",Anticipated,2020-07-20,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,CPC-SARS,,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial",Recruiting,NA,Phase 2,80,Anticipated,Grupo Mexicano para el Estudio de la Medicina Intensiva,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,3 months after completion up to five years,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2020-06-02T08:27:27Z,2020-06-02T08:27:27Z
NCT04410562,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-26,NA,NA,2020-05-29,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"May 13, 2020",Actual,2020-05-13,April 2020,2020-04-30,"August 1, 2021",Anticipated,2021-08-01,"May 13, 2021",Anticipated,2021-05-13,NA,Interventional,COVID-Preg,,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Recruiting,NA,Phase 3,714,Anticipated,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,By the end of study,NA,NA,Yes,It would be shared at time of publication.,2020-06-06T08:46:25Z,2020-06-06T08:46:25Z
NCT04405544,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-26,NA,NA,2020-05-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 22, 2020",Actual,2020-05-22,May 2020,2020-05-31,"October 22, 2020",Anticipated,2020-10-22,"July 22, 2020",Anticipated,2020-07-22,NA,Interventional,NA,,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Recruiting,NA,N/A,60,Anticipated,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-06T08:47:56Z,2020-06-06T08:47:56Z
NCT04409496,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-26,NA,NA,2020-06-02,2020-05-26,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"June 30, 2021",Anticipated,2021-06-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Chat-based Support for Preveting Smoking Relapse,Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial,Recruiting,NA,N/A,100,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:30:45Z,2020-06-08T08:30:45Z
NCT04410692,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-27,NA,NA,2020-05-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Interventional,NA,,Can the Prediction Market Improve Predictions of COVID-19?,Can the Prediction Market Improve Predictions of COVID-19?,Completed,NA,N/A,560,Actual,"National University, Singapore",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,After completion of all analysis. It will be made available in the supporting documentation.,It will be made available in the supporting documentation.,NA,Yes,"Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.",2020-06-07T08:40:28Z,2020-06-07T08:40:28Z
NCT04416308,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-27,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 29, 2020",Actual,2020-05-29,June 2020,2020-06-30,"November 10, 2020",Anticipated,2020-11-10,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,AntiCoV-HB,,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne,Recruiting,NA,N/A,13000,Anticipated,Rennes University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-06-08T08:28:33Z,2020-06-08T08:28:33Z
NCT04408131,"ClinicalTrials.gov processed this data on June 02, 2020",2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,"January 27, 2021",Anticipated,2021-01-27,"January 27, 2021",Anticipated,2021-01-27,NA,Interventional,COVIDHomeless,,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,NA,N/A,2000,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-03T08:29:04Z,2020-06-03T08:29:04Z
NCT04409743,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,June 2020,Anticipated,2020-06-30,May 2020,2020-05-31,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,"Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms",Recruiting,NA,N/A,100,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-06T08:46:53Z,2020-06-06T08:46:53Z
NCT04409522,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"June 5, 2020",Anticipated,2020-06-05,NA,Interventional,NA,,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,NA,N/A,55,Anticipated,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-06T08:47:01Z,2020-06-06T08:47:01Z
NCT04409327,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults â‰¥65 Years in a Nursing Home in Which â‰¥1 Person(s) Have Lab Confirmed COVID19,Recruiting,NA,Phase 3,550,Anticipated,Restorbio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-06T08:47:11Z,2020-06-06T08:47:11Z
NCT04412486,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-28,NA,NA,2020-05-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma (CCP) Transfusion,An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19,Recruiting,NA,Early Phase 1,100,Anticipated,University of Mississippi Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-07T08:39:27Z,2020-06-07T08:39:27Z
NCT04410458,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-29,NA,NA,2020-05-29,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"May 31, 2020",Anticipated,2020-05-31,May 2020,2020-05-31,"June 12, 2020",Anticipated,2020-06-12,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,NA,N/A,506517,Anticipated,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-06T08:46:28Z,2020-06-06T08:46:28Z
NCT04412343,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-29,NA,NA,2020-05-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 30, 2020",Anticipated,2020-05-30,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,SCOPE,,The Seniors COvid-19 Pandemic and Exercise Study,The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial,Recruiting,NA,N/A,600,Anticipated,University of British Columbia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available from this trial 1 year after completion of the study. The data will remain available indefinitely.,"The nature of the request for sharing access will be reviewed by the PI (Beauchamp, M) and the data management team. Data will be shared via secure platforms (Redcap). Contact for data access can be done through personal communications (e.g., email) with PI Beauchamp.",https://osf.io/xw9gm,Yes,"The protocol for this study will be available on Open Science Framework (after 4 months to allow for study completion). The Statistical Analysis Plan will also be available on Open Science Framework. The Consent form is freely available if requested from the Primary Investigator (PI: Beauchamp, M.).",2020-06-07T08:39:33Z,2020-06-07T08:39:33Z
NCT04411667,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-29,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Recruiting,NA,Phase 4,40,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-06-07T08:40:00Z,2020-06-07T08:40:00Z
NCT04415073,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-29,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 30, 2020",Actual,2020-05-30,June 2020,2020-06-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Axatilimab for the Treatment of Hospitalized Patients With Respiratory Signs and Symptoms Secondary to Novel Coronavirus Disease (COVID-19)",Recruiting,NA,Phase 2,186,Anticipated,Syndax Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:29:22Z,2020-06-08T08:29:22Z
NCT04412018,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-29,NA,NA,2020-06-03,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),Recruiting,NA,Phase 2,100,Anticipated,Canadian Medical and Surgical Knowledge Translation Research Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-08T08:30:31Z,2020-06-08T08:30:31Z
NCT04411628,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-29,NA,NA,2020-06-02,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 28, 2020",Actual,2020-05-28,June 2020,2020-06-30,"August 23, 2020",Anticipated,2020-08-23,"August 23, 2020",Anticipated,2020-08-23,NA,Interventional,NA,,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Recruiting,NA,Phase 1,40,Anticipated,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-08T08:30:34Z,2020-06-08T08:30:34Z
NCT04412239,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-30,NA,NA,2020-05-30,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"September 20, 2020",Anticipated,2020-09-20,"August 20, 2020",Anticipated,2020-08-20,NA,Interventional,NA,,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,NA,N/A,200,Anticipated,Health Science Center of Xiâ€™an Jiaotong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-07T08:39:36Z,2020-06-07T08:39:36Z
NCT04416139,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-30,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 1, 2021",Anticipated,2021-05-01,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,COVID-19,,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study,Recruiting,NA,Phase 2,10,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:28:39Z,2020-06-08T08:28:39Z
NCT04414371,"ClinicalTrials.gov processed this data on June 05, 2020",2020-05-31,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,NA,N/A,200,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:29:49Z,2020-06-08T08:29:49Z
NCT04412772,"ClinicalTrials.gov processed this data on June 05, 2020",2020-06-01,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,ARCHITECTS,,A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19",Recruiting,NA,Phase 3,300,Anticipated,Queen's Medical Centre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-06-07T08:39:17Z,2020-06-07T08:39:17Z
NCT04414267,"ClinicalTrials.gov processed this data on June 05, 2020",2020-06-01,NA,NA,2020-06-03,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Estimate,"May 26, 2020",Actual,2020-05-26,June 2020,2020-06-30,"May 25, 2021",Anticipated,2021-05-25,"May 25, 2021",Anticipated,2021-05-25,NA,Interventional,ACTIVATEII,,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Recruiting,NA,Phase 4,900,Anticipated,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:29:53Z,2020-06-08T08:29:53Z
NCT04414124,"ClinicalTrials.gov processed this data on June 05, 2020",2020-06-01,NA,NA,2020-06-01,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19",Recruiting,NA,N/A,400,Anticipated,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-06-08T08:29:58Z,2020-06-08T08:29:58Z
NCT04412668,"ClinicalTrials.gov processed this data on June 05, 2020",2020-06-01,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,"aTyr Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-06-08T08:30:27Z,2020-06-08T08:30:27Z
